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ABSTRACT
The hyperpolarization activated cyclic nucleotide gated ion channels (HCN) are encoded
by 4 isoforms (HCN1-4). These are nonspecific cation channels which mediate the slow inward
current Ih. Dysregulation of HCN2 contributes to multiple disease states such as epilepsy,
depression and anxiety, and chronic pain. The HCN2 channel is post-translationally modified by
the small ubiquitin like modifier (SUMO), where SUMOylation of K669 is associated with an
increase in Ih and surface expression. This dissertation work investigates how ion channel
SUMOylation regulates hyperexcitability in inflammatory pain. Following complete Freund’s
adjuvant (CFA) induced inflammation, there is an increase in HCN2 protein level bilaterally, and
a unilateral increase in pain behavior. Interestingly, we observe an increase in HCN2
SUMOylation unilaterally following inflammation suggesting that SUMOylation of HCN2 may
play an important role in regulating Ih in inflammation. We examine the molecular mechanisms
driving the increase in Ih and surface expression following SUMOylation of K669 in HCN2.
Surface expression can be increased by promoting trafficking from the trans-Golgi to the plasma
membrane, by reducing channel endocytosis and/or by increasing recycling of the endocytosed
channel. Indeed, SUMOylation of HCN2 increases colocalization with the slow recycling
marker, Rab11a, and a dominant negative form of Rab11a blocks the SUMO mediated increase
in Ih. Together these results suggest a potential mechanism behind the increase in Ih in
inflammatory pain. Additionally, investigating the mechanism behind SUMO regulation of
another ion channel, Kv4.2, we observe a Rab11a mediated increase in IA. These findings
suggest C-terminal SUMOylation of ion channels may represent a general mechanism for
regulating the extent of ion channel recycling.
INDEX WORDS: Small ubiquitin-like modifier (SUMO), Ion channels, Pain, Inflammation,
HCN2, Trafficking, Voltage gated ion channels
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INTRODUCTION
1.1

Pain and inflammation
Chronic pain is a major challenge to our society, with serious impacts on life for those

who are facing this debilitating condition, as well as significant impacts to the economy. It has an
estimated cost burden of $635 billion a year to American society (Chapman & Vierck, 2017).
Over the past two decades incidence of chronic pain in US adults has increased by ~10%
(Zajacova, Grol-Prokopczyk, & Zimmer, 2021). The 2012 National Health Interview survey
showed that 25.3 million US adults experienced chronic pain daily with even greater numbers,
40 million, experiencing severe pain (Blackwell, Lucas, & Clarke, 2014). Those with severe pain
displayed worse health than those reporting less severe pain. The trend toward increasing pain is
worrisome and drives urgency in increasing our understanding of the mechanisms behind chronic
pain. Here, I describe and discuss pain as the summed experience of a real or perceived noxious
sensory stimuli (painful, threatening stimuli), as well as the emotional and cognitive response
(Dubin & Patapoutian, 2010); nociception is the detection of the stimuli. Chronic pain is defined
as pain lasting beyond tissue damage and inflammatory processes associated with tissue healing
(Chapman & Vierck, 2017). Chronic pain displays alterations to the normal pain pathway,
showing hypersensitivity. These signs show that the pain has extended past its usefulness as a
warning sign of impending tissue damage, and now becomes debilitating. Symptoms of chronic
pain can be viewed during normal healing to some degree. For example, during normal healing, a
person with sunburn will display allodynia, where a normal innocuous stimuli is perceived as
painful, such as what would normally be a pleasant warm shower feeling painful and burning,
from sensitization to both the temperature of the water and the touch from the water pressure on
the skin (Basbaum, Bautista, Scherrer, & Julius, 2009). Additionally, someone could display
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hyperalgesia, the exaggerated response to a normally noxious stimulus. These symptoms come
about in response to reorganization of the pain circuitry, where ionic conductances are altered in
a maladaptive manner to cause hyperalgesia or allodynia when they would not normally occur.
This is normally in response to some insult – whether that is inflammation as in the case of
arthritis (Muley, Krustev, & McDougall, 2016), or nerve damage as in the case of diabetic
neuropathy (Calcutt, 2020), where the sensory neurons become hyperexcitable by the alterations
in their ionic conductances (Berta, Qadri, Tan, & Ji, 2017; Gold & Gebhart, 2010; Pace et al.,
2018; Reichling & Levine, 2009). Nociceptors are peripheral sensory neurons. They detect
noxious temperature, pressure, and chemical stimuli and initiate pain signaling in response to
this. They are pseudounipolar neurons with a single process from the soma which bifurcates
forming the t-junction. One process projects to the periphery, such as the skin or viscera, and the
other process to the spinal cord to innervate the central nervous system. The soma of these
neurons resides in the dorsal root ganglia (DRG), and the trigeminal ganglia (Devor, 1999). The
nociceptors of the DRG can be classified into three groups based on their conduction velocities
and degree of myelination. C-fibers display the slowest conduction velocity, 0.6m/s, with small
diameter and unmyelinated axons. Aδ fibers are small to medium diameter axons that are thinly
myelinated with a conduction velocity of 3.3m/s, and Aβ nociceptors have large diameter axons
that are thickly myelinated with a conduction velocity of 9.6m/s (Djouhri & Lawson, 2004).

1.2

The role of Ih in pain
The hyperpolarization activated cyclic nucleotide gated ion channels (HCN) are voltage

gated ion channels that are activated by hyperpolarizing membrane potentials. They are
nonspecific cation channels, and mediate a hyperpolarization activated current, Ih, which is a
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slow inward current. This current has been termed a pacemaker current as it plays a role in
initiation and regulation of the heartbeat and is involved in regulation of rhythmic currents in
neural circuits (Baruscotti, Bucchi, & Difrancesco, 2005; Wahl-Schott & Biel, 2009). There are 4
isoforms, 1-4, which vary in their responsiveness to cAMP. Binding of cAMP to the cyclic
nucleotide binding domain (CNBD) speeds up channel opening and shifts the voltage of
activation to more positive voltages. Isoforms 2 and 4 are the most responsive to cAMP, with
shifts of between +10 to +25mV observed upon cAMP binding, where 1 and 3 are only weakly
affected by cAMP (Wahl-Schott & Biel, 2009). HCN channels can form homologous or
heterologous tetramers(Tibbs, Posson, & Goldstein, 2016). Ih contributes to neuronal excitability
by generating a depolarizing current that aids in restoring the membrane potential of a cell
towards firing threshold. HCN channels play a role in homeostatic regulation of cells by either
activating when needed to increase a cells activity or deactivating to decrease activity. There is
some proportion of channels open at resting membrane potential; this causes there to be a slow
tonic influx of Na+ ions into the cell, bringing the membrane potential to more depolarized
values and is able to stabilize the membrane potential in subthreshold ranges. (Hutcheon &
Yarom, 2000; Kase & Imoto, 2012; Shah, 2014; Wahl-Schott & Biel, 2009). Dysregulation of
HCN channels can contribute to multiple neurological disease states (DiFrancesco &
DiFrancesco, 2015). In epilepsy, genetic deletions of HCN2 leads to absence epilepsy
phenotypes, loss of HCN expression occurs during the beginning of epileptogenesis in acquired
epilepsy, and seizures promote changes in the pattern of HCN expression (Poolos, 2012). In
major depression, rodent models of chronic social defeat display a decrease in HCN2 mediated
currents in the ventral tegmental area which contribute to depressive and anxiety-like behaviors
(Zhong et al., 2018). In Alzheimer’s disease HCN2 mediated currents contribute to the
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processing of Amyloid precursor protein (APP), as inhibition of the current with the Ih blocker
ZD7288 showed decreased levels of Aβ and other APP cleavage products (Frykman et al., 2017).
Additionally, HCN channels have been found to contribute to the development of pain.
Ih is increased in several models of chronic inflammatory and neuropathic pain in
nociceptors (Djouhri et al., 2015; Emery, Young, Berrocoso, Chen, & McNaughton, 2011;
Schnorr et al., 2014; Weng, Smith, Sathish, & Djouhri, 2012). Following CFA injection rats
display inflammatory hypersensitivity, unilaterally, for at least 14 days as displayed by a
decrease in the paw withdrawal threshold (Stein, Millan, & Herz, 1988). When a HCN channel
blocker, ZD7288 is applied at 5 days post CFA there is a partial reverse of mechanical
hypersensitivity (Weng et al., 2012). Additionally, when HCN2 channels specifically, are
knocked out in NaV1.8-expressing neurons in mice failed to develop mechanical
hypersensitivity, but still developed thermal hyperalgesia (Schnorr et al., 2014). The HCN2
isoform has been implicated in both inflammatory and neuropathic pain. For inflammatory pain,
in the dorsal root ganglia increases in HCN2 immunoreactivity were observed at 1, 4 and 7 days
post CFA induced inflammation in small and medium diameter DRG neurons, which
corresponds to putative c-fiber nociceptors and Aδ nociceptors (Acosta et al., 2012; Weng et al.,
2012).

1.3

The role of extranuclear SUMOylation
The small ubiquitin like modifier (SUMO) is a small ~100 amino acid protein that is a

reversible, post-translational modification added to lysine residues in target proteins. SENPs, are
SUMO proteases that remove SUMO from target residues. SENPs also aid in maturation of
SUMOylation, they cleave the c-terminus to expose a di-glycine motif which is able to form a

Regulation of HCN2 by SUMOylation

5

thioester bond with the SUMO E1 enzyme. This step is ATP-dependent. Next activated SUMO
is transferred to the sole E2 conjugating enzyme, Ubc9. Finally, SUMO is added to target
proteins by the E2 enzyme alone, or with assistance from an E3 enzyme (Vertegaal, 2022)
(Figure 1). The majority of SUMOylation, ~65% occurs within a SUMO consensus motif
(Hendriks, D'Souza, Chang, Mann, & Vertegaal, 2015), ψKXE (where ψ represents a
hydrophobic amino acid and X represents any amino acid), but SUMOylation also occurs at nonconsensus K residues. Specificity for non-consensus SUMOylation can be guided through
interaction with a SUMO interaction motif (SIM) in the target protein and recruiting the ubc9SUMO thioester bond this way, or interaction of the target with an E3 ligase to position the
SUMO in an orientation to aid in modification of the residue (Flotho & Melchior, 2013). There
are 5 SUMO peptides, SUMO1-5, where SUMO2 and 3 are 97% identical and not readily
distinguishable and often referred to as SUMO2/3, and SUMO1 is 47% similar to SUMO2/3.
SUMO4 is likely not conjugated to substrates due to its specific amino acid sequence preventing
SUMO maturation. SUMO 5 has been recently reported, but it’s endogenous expression has not
yet been confirmed suggesting it might be a SUMO pseudogene (Vertegaal, 2022).
SUMOylation was first discovered in the nucleus, and as such a large body of
research focuses on its role there. Staining for SUMO with antibodies shows intense staining in
the nucleus, and diffuse staining in the cytoplasm (See figure 2-1). In the nucleus one of the most
well-defined roles of SUMOylation is its involvement in DNA damage repair where
SUMOylation acts as a “glue”, holding together the proteins involved in homologous
recombination and nucleotide excision repair (Jentsch & Psakhye, 2013; Psakhye & Jentsch,
2016). Other roles of nuclear SUMOylation include SUMOylation of transcription factors to
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enhance or repress transcription, formation of PML nuclear bodies, chromosome organization,
and nuclear transport (Johnson, 2004). Proteins outside of the nucleus are also SUMOylated.
In neurons, extranuclear SUMOylation is involved in the development of the nervous
systems, for proper differentiation, development of rods and cones in the retina, synapse
formation, and regulation of excitability by regulating ion channels (Henley, Craig, & Wilkinson,
2014). In addition to HCN2, other ion channels are known to be SUMOylated. The potassium
channels Kv4 (Meghyn A. Welch, Lori A. Forster, Selin I. Atlas, & Deborah J. Baro, 2019),
Kv11 (Steffensen, Andersen, Mutsaers, Mujezinovic, & Schmitt, 2018), Kv7 (Qi et al., 2014;
Xiong et al., 2017), Kv2 (Plant, Dowdell, Dementieva, Marks, & Goldstein, 2011), K2P1 (Plant
et al., 2010; Rajan, Plant, Rabin, Butler, & Goldstein, 2005) and Kv1.5 (Benson et al., 2007) as
well as SUMOylation of the sodium channels NaV1.2 (Plant, Marks, & Goldstein, 2016) and
NaV1.5 (Plant, Xiong, Romero, Dai, & Goldstein, 2020), and the calcium channels CaV2.2
(Silveirinha et al., 2021) TRPV1 (Y. Wang et al., 2018b) and TRPM4 (Kruse et al., 2009), the
Na+/Ca2+ exchanger (Cuomo et al., 2020) are SUMOylated.
The HCN2 ion channel is SUMOylated in rat nervous system tissue (Forster, Jansen,
Rubaharan, Murphy, & Baro, 2020a; Parker et al., 2016). In HEK293 cells HCN2 channel
SUMOylation can be enhanced by over expression of a plasmid containing the E2 conjugating
enzyme, ubc9, and a plasmid encoding SUMO2. When SUMOylation of the channel is
enhanced, the surface expression of the channel is increased as well as the maximal conductance.
This is due to modification of K669, as mutation of the lysine to arginine prevented an increase
in both surface expression and maximal conductance. Another high probability SUMOylation
site, K534, did not influence either of these measures in this heterologous system (Parker et al.,
2017). Additionally, HCN channel SUMOylation is dopamine and activity dependent. Tonic,
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5nM levels of dopamine, permitted activity to regulate Ih in the lobster stomatogastric nervous
system. These effects were occluded by perfusion of a cell-permeable tat-tagged active SUMO
peptide (Parker, Forster, & Baro, 2019) suggesting that DA permitted activity dependent
SUMOylation of the HCN channel, where SUMOylation increased Ih.

1.4

Hypothesis
How does ion channel SUMOylation regulate neuronal hyperexcitability in

inflammation? This work uses a rat model of complete Freund’s adjuvant induced inflammation
to test the hypothesis that the HCN2 ion channel is differentially SUMOylated during
inflammatory pain. It also uses a heterologous expression system to examine how posttranslational SUMOylation regulates HCN2 surface expression and maximal conductance. In
Chapter 2, SUMOylation of HCN2 in the DRG is shown, and in chapters 2 and 3 the pattern of
HCN2 SUMOylation in lumbar levels 4-6 over 1-3 days following inflammation is
characterized. In Chapter 4 the mechanism of regulation of surface expression of the HCN2
channel is examined after post-translational modification by SUMO, as well proposing a
common mechanism in regulating other ion channels by SUMO.
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Figure 0-1-1 The SUMO Pathway
Inactive SUMO has c-terminal amino acids cleaved by SENP to expose a diglycine motif
allowing it to be conjugated. Active SUMO is transferred to the E1 enzyme in an ATP dependent
fashion. The sole E2 conjugating enzyme can conjugate SUMO to target lysine (K) residues on
it’s own, or can utilize an E3 enzyme to aid in target specificity. Figure modified from Flotho &
Melchior, 2013 (Flotho & Melchior, 2013).
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ALTERATIONS IN SUMOYLATION OF THE HYPERPOLARIZATIONACTIVATED CYCLIC NUCLEOTIDE GATED ION CHANNEL 2 DURING
PERSISTENT INFLAMMATION

Publication: Forster LA, Jansen LR, Rubaharan M, Murphy AZ, Baro DJ. 2020. Alterations in
SUMOylation of the hyperpolarization-activated cyclic nucleotide-gated ion channel 2 during
persistent inflammation. Eur J Pain. doi:10.1002/ejp.1606

Contribution Disclosure: Authors L. Forster, L-A. Jansen, AZ Murphy and D. Baro were
responsible for the conception and design of the research presented. M. Rubaharan performed
animal experiments. Authors L. Forster, L-A. Jansen contributed to the acquisition and analysis
of the data. Authors L. Forster and L-A. Jansen contributed equally. Authors L. Forster, L-A
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Jansen and D. Baro were responsible for drafting the manuscript, and all authors were involved
in revising the manuscript.
2.1

Abstract

Unilateral injection of Complete Freund’s Adjuvant (CFA) into the intra-plantar surface of the
rodent hindpaw elicits chronic inflammation and hyperalgesia in the ipsilateral hindlimb.
Mechanisms contributing to this hyperalgesia may act over multiple time courses and can
include changes in ion channel expression and post-translational SUMOylation.
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels mediate the
hyperpolarization-activated current, Ih. An HCN2-mediated increase in C-nociceptor Ih
contributes to mechanical hyperalgesia in the CFA model of inflammatory pain. Changes in
HCN2 post-translational SUMOylation and protein expression have not been systematically
documented for a given DRG throughout the time course of inflammation.This study examined
HCN2 protein expression and post-translational SUMOylation in a rat model of CFA-induced
hindpaw inflammation. L5 DRG cryosections were used in immunohistochemistry experiments
and proximity ligation assays to investigate HCN2 expression and SUMOylation, respectively,
on days 1 and 3 post-CFA. Unilateral CFA injection elicited a significant bilateral increase in
HCN2 staining intensity in small diameter DRG neurons on day 1 post-CFA, and a significant
bilateral increase in the number of small neurons expressing HCN2 but not staining intensity on
day 3 post-CFA. HCN2 channels were hyper-SUMOylated in small diameter neurons of
ipsilateral relative to contralateral DRG on days 1 and 3 post-CFA. Unilateral CFA injection
elicits unilateral mechanical hyperalgesia, a bilateral increase in HCN2 expression and a
unilateral increase in post-translational SUMOylation. This suggests that enhanced HCN2
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expression in L5 DRG is not sufficient for mechanical hyperalgesia in the early stages of
inflammation and that hyper-SUMOylation of HCN2 channels may also be necessary.
2.2

Significance

Nociceptor HCN2 channels mediate an increase in Ih that is necessary for mechanical
hyperalgesia in a CFA model of chronic pain, but the mechanisms producing the increase in
nociceptor Ih have not been resolved. The data presented here suggest that the increase in Ih
during the early stages of inflammation may be mediated by an increase in HCN2 protein
expression and post-translational SUMOylation.
2.3

Introduction

Nociceptor signaling is increased in chronic pain states due, in part, to maladjustments in sensory
neuron ionic conductances (Berta et al., 2017; Gold and Gebhart 2010; Pace et al., 2018;
Reichling and Levine 2009). In most cases, the molecular and cellular processes leading to this
peripheral sensitization are poorly understood. Mounting evidence suggests that widespread
alterations in ion channel SUMOylation may contribute to conductance changes underpinning
hyperalgesia associated with chronic pain.
Small ubiquitin like modifier (SUMO) is a ~12kDa peptide that is reversibly conjugated
to lysine (K) residues of target proteins (Flotho and Melchior 2013). The majority of
SUMOylation (~65%) occurs within identifiable consensus sequences (Hendriks et al., 2015).
The phosphorylation status of a target protein often determines its ability to be SUMOylated
(Dustrude et al., 2016). Additionally, the level of target protein SUMOylation depends upon the
ratio of 2 opposing enzyme activities: conjugation by ubc9 and deconjugation by isopeptidases,
the best studied being the SENP family (isoforms 1-7) (Kunz et al., 2018). A variety of E3
proteins can also stabilize ubc9-target protein interactions to promote SUMOylation (Flotho and
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Werner 2012; Koidl et al., 2016; Werner et al., 2012). Of the 4 SUMO isoforms, SUMO1-3 are
well-studied but the physiological relevance of SUMO4 is unclear (Watts 2013). SUMO2 and
SUMO3 are 97% identical, and are referred to as SUMO2/3. SUMO1 shares 47% identity with
SUMO2/3. Non-mutually exclusive consequences of target protein SUMOylation include: 1)
prevention of other modifications that occur on the same K (Anderson et al., 2012); 2) binding to
phosphoinositides (PIPs) concentrated in the trans-Golgi [PI(3)P] and plasma membrane
[PI(3,4,5)P3] (Arendt et al., 2010; Hammond and Burke 2020; Kunadt et al., 2015); 3)
prevention of protein-protein interactions through steric hindrance (Dustrude et al., 2016); and
most commonly, 4) promotion of protein-protein interactions through binding domains in partner
proteins that recognize SUMO (Psakhye and Jentsch 2012; Seifert et al., 2015).
Extracellular signaling and neuronal activity regulate the location and activity of the
SUMOylation machinery and the SUMOylation status of target proteins (Craig et al., 2012;
Hendriks et al., 2015; Loriol et al., 2013; Parker et al., 2019; Seifert et al., 2015). Both
extracellular signals and nociceptor activity are altered during CFA-induced persistent
inflammation, and a generalized increase in SUMOylation is observed in the DRG (Wang et al.,
2018b). SUMOylation of TRPV1 channels is necessary for thermal hyperalgesia during CFAinduced persistent inflammation, and increasing SUMOylation by genetic knock-out of SENP1
in sensory neurons exacerbates thermal hyperalgesia during CFA-induced persistent
inflammation (Wang et al., 2018b). SUMOylation of the NaV1.7 auxiliary subunit, CRMP2,
prevents channel endocytosis (Dustrude et al., 2016). CRMP2 was hyper-SUMOylated in
primary sensory afferents in a rat spared nerve injury model of chronic neuropathic pain, and
blocking CRMP2 hyper-SUMOylation prevented mechanical and thermal hyperalgesia in this
model (Dustrude et al., 2016; Dustrude et al., 2013; Francois-Moutal et al., 2018; Moutal et al.,
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2017). These data suggest that nociceptor ion channel hyper-SUMOylation contributes to
hyperalgesia during chronic inflammatory and neuropathic pain.
Several ion channel subunits can be SUMOylated. Existing data generally suggest that
hyper-SUMOylation of ion channel subunits increases cell excitability. Enhancing K+ channel
SUMOylation reduces outward currents mediated by Kv4 (Welch et al., 2019), Kv11 (Steffensen
et al., 2018), Kv7 (Qi et al., 2014; Xiong et al., 2017), Kv2 (Plant et al., 2011), and K2P1 (Plant
et al., 2010; Rajan et al., 2005). To our knowledge, only Kv1.5 does not fit this pattern and is
increased by hyper-SUMOylation (Benson et al., 2007), however, Kv1.5 is not highly expressed
in nociceptors (Zheng et al., 2019). Conversely, inward conductances are generally enhanced by
hyper-SUMOylation, including conductances mediated by HCN2 (Parker et al., 2017), NaV1.2
(Plant et al., 2016), NaV1.7 (Dustrude et al., 2016) and TRPV1 (Wang et al., 2018a). While
SUMO modulation of ion channels may be much more complex and vary according to which
sites on the ion channel are SUMOylated (Welch et al., 2019), the data suggest a generalized
increase in nociceptor ion channel SUMOylation could lead to increased excitability.
The nociceptor hyperpolarization-activated current (Ih) is increased in several models of
chronic inflammatory and neuropathic pain (Djouhri et al., 2015; Emery et al., 2011; Schnorr et
al., 2014; Weng et al., 2012). Ih plays a pivotal role in shaping neuronal excitability and synaptic
integration by influencing several neuronal activity features including membrane potential, firing
threshold, resonance frequency, temporal summation, and synaptic strength (Hutcheon and
Yarom 2000; Shah 2014; Wahl-Schott and Biel 2009). Hyperpolarization-activated cyclic
nucleotide gated ion channels (HCN) mediate Ih (Sartiani et al., 2017). There are four HCN
isoforms. Genetic ablation of HCN2 in primary sensory afferents prevented mechanical and
thermal hyperalgesia in a chronic constriction injury model of neuropathic pain (Emery et al.,
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2011) and mechanical hyperalgesia in a CFA model of persistent inflammation (Schnorr et al.,
2014). HCN2 protein expression increases in small DRG neurons during CFA-induced persistent
inflammation (Acosta et al., 2012; Weng et al., 2012). HCN2 is SUMOylated by both SUMO1
and SUMO2/3 in the rodent brain (Parker et al., 2017). SUMOylation of HCN2 at K669
increases channel surface expression and Ih in a heterologous expression system (Parker et al.,
2017). Here we investigate changes in HCN2 expression and SUMOylation in rat L5 DRG on
days 1 and 3 of CFA-induced inflammation.
2.4

Materials and methods

2.4.1 Animal Ethics
Ethics approval was obtained from the Institutional Animal Care and Use Committee at
Georgia State University, and all experiments were performed in compliance with Ethical Issues
of the International Association for the Study of Pain and National Institutes of Health (NIH).
Male Sprague-Dawley rats (Charles-River, MA) were pair-housed on a 12-hour light/dark cycle
(lights on at 0700 hours) with ad libitum access to food and water.
2.4.2 CFA model and tissue preparation
60 day old male Sprague-Dawley rats were injected with 200 µl of CFA (Sigma, F5881,
1 ml contains 1 mg of heat-killed and dried Mycobacterium tuberculosis (strain H37Ra, ATCC
25177), 0.85 ml paraffin oil and 0.15 ml of mannide monooleate) into the mid-plantar surface of
the right hindpaw. Control rats were handled, but did not receive CFA injections. Either 1 or 3
days later rats were anesthetized with 600 µl of sodium pentobarbital (390 mg/ml) in phenytoin
sodium (50 mg/ml) followed by an intracardiac injection of heparin (NDC 25021-400-30, 1000
USP units/mL). Animals were perfused with ~200 ml of sodium nitrite saline followed by 350
ml of 4% paraformaldehyde. Hindpaws were measured. CFA-treated rats showed a significant
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increase in ipsilateral hindpaw width relative to contralateral hindpaw width (p=0.0003). Control
rats showed no change (p>0.9999). After fixation, bilateral L5 DRG were identified by counting
down from T13 (located at the last rib) to L6. L5 DRG were dissected and placed into 18%
sucrose at 4ºC overnight. The next day, the epineurium of each DRG was removed. DRG were
embedded in 0.3% gelatin and sliced in 20 µm cryosections (Leica CM3050 S); slices were
stored at 4ºC for short-term storage (<2 months), or at -80ºC for longer-term storage.
2.4.3 Antibodies and reagents
The HCN2 polyclonal rabbit antibody (Alomone, APC-030, Jerusalem) concentration
used was 1:200 for Proximity Ligation Assays (PLA) and 1:250 for immunohistochemistry
(IHC) experiments, 5 g for immunoprecipitations (IP), and 1:1000 for Western Blots. A
secondary Alexa 488 goat anti-rabbit was used at 1:400 (Jackson ImmunoResearch, PA) for IHC
experiments. For PLA, a monoclonal mouse antibody against SUMO1 (Santa Cruz, Sc-5308)
was used at 1:100, and a monoclonal mouse antibody against SUMO2/3 (Developmental Studies
Hybridoma Bank, SUMO-2 8A2) was used at a concentration of 1:70 and developed by Matinus,
M. at John Hopkins School of Medicine, created by the NICHD of the NIH and maintained at
The University of Iowa, Department of Biology, Iowa City, IA 52242. All chemicals were
obtained through Sigma-Aldrich unless otherwise stated.
2.4.4 Immunohistochemistry
A cryosection was encircled with a hydrophobic pen (Vector Laboratories), washed once
with 0.1 M PBS, twice with HBSS, and incubated with 3.5 g/mL of Wheat Germ Agglutinin
CF® 594 (Biotium) to stain membranes. The cryosection was serially washed 2x times with
HBSS, once with 0.1 M PBS, and permeabilized with 0.1 M PBS with 0.2% Triton X-100 (PBST). The cryosection was blocked for 30 minutes with 10% normal goat serum in PBS-T and
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incubated with diluted anti-HCN2 in PBS-T overnight at room temperature. The cryosection was
serially washed 3x times with 0.1 M PBS and incubated with Alexa 488 goat anti-rabbit diluted
in 0.1 M PBS for 3 hours at room temperature. The cryosection was washed 3x in 0.1 M PBS
and incubated with Dapi (300 nM) for 5 minutes. Serial washes with 0.1 M PBS were repeated
3x times, and the cryosection was mounted with ProLong Gold antifade reagent (Thermo-Fisher
Scientific). All incubations were performed in a humidity chamber with a minimum volume of
17 l per cryosection. IHC experiments were repeated on 7 experimental animals and 3 control
animals for day 1, and 5 experimental animals and 4 control animals for day 3.
2.4.5 Immunohistochemistry analysis
Blind analyses were performed. DRG images were taken at 5x total magnification using
an Olympus BX43 fluorescence microscope and cellSens software. Three images were taken per
DRG. Images were analyzed with Photoshop. Each image was thresholded to remove the
intensity of the sheath by successively increasing the tolerance of the magic wand tool. All
remaining cells were considered HCN2 positive and were quantified if they showed a definitive
nucleus and visible cell perimeter. Cells not meeting these criteria were ignored. All HCN2
positive cells were selected using the magnetic lasso tool and the diameter and gray mean values
for each selection were obtained using the measurement feature. Cells were then classified by
diameter: small  30 m, medium 31- 40 m, large  40 m. The gray mean values for all cells
in each neuronal size class were averaged and taken to be the mean intensity for the size class.
To measure frequency for each size class, the number of HCN2 positive cells in a class were
divided by the total number of cells meeting the quantification requirements.
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2.4.6 Proximity ligation assay (PLA)
Proximity ligation assays were performed using Duolink® in situ Red kit (SigmaAldrich) following manufacturer’s instructions. Briefly, DRG cryosections were washed once in
0.1 M PBS, twice in HBSS then incubated with 5 µg/ml Wheat Germ Agglutinin-FITC (SigmaAldrich) to stain membranes. DRG sections were washed twice times with HBSS, once with 0.1
M PBS permeabilized with PBST. Each cryosection was blocked using 17 µl of Duolink®
blocking solution for 30 minutes at 37ºC. Primary antibodies were diluted in Duolink® antibody
diluent, 17 µl was applied to each cryosection and incubated overnight at room temperature.
Slides were washed three times for 15 minutes in 0.1 M PBS, and incubated with Duolink® antimouse minus and Duolink® anti-rabbit plus secondaries for 1 hour at 37ºC. Slides were washed
twice with Duolink® wash buffer A. The ligation reactions were performed at 37ºC for 30
minutes. Slides were washed twice for 2 minutes with wash buffer A. The amplification reaction
time was extended by 10% to 110 minutes at 37ºC. Slides were washed twice for 10 minutes in
wash buffer B then once in 0.1x wash buffer B before mounting with Vectashield non-hardening
mounting medium (Vector laboratories, H-1000). Slides were sealed with clear nail varnish. All
incubations were performed in a humidity chamber. All washes with PLA wash buffers A or B
were performed in a minimum volume of 70 ml. PLA experiments using SUMO2/3 were
repeated on 6 experimental animals and 3 control animals at 1 day, and on 7 experimental
animals and 4 control animals at day 3. PLA experiments using SUMO1 were repeated on 6
experimental animals and 4 control animals at day 1, and 6 experimental animals and 3 control
animals at day 3.

Regulation of HCN2 by SUMOylation

18

2.4.7 PLA analysis
Blind analyses were performed. Images were acquired with a Zeiss 700 confocal
microscope using a 40x oil immersion objective within 5 days of the PLA experiment. Three
sections were analyzed per DRG. For each section, a minimum of 3 z-stacks was acquired.
Optical slices were 0.9 µm thick with an interval of 1 µm. Images were analyzed using the FIJI
version of ImageJ. A maximum projection was created from 5 z-slices from the center of a cell.
A projection contained a visible nucleus and clear cell boundaries and did not overlap with
neighboring cells or fibers. Cells were outlined, and thresholded using the triangle method. The
triangle method assumes that the intensity of the image is skewed in one direction and finds a
value where the skew from background intensity is removed, leaving only signal above that
value. Watershed analysis was performed to divide any coalesced signals. The analyze particle
feature was used to obtain puncta number, mean pixel intensity and area for each punctum, as
well as the area of the cell and Feret’s diameter. Mean pixel intensity (MPI) of the puncta within
1 cell was obtained by a program developed by Alex Perez, to calculate the average mean puncta
intensity within 1 cell and allow us to batch process large amounts of data.
2.4.8 Rat DRG membrane preparation and denaturing immunoprecipitation
Approximately 50 DRG were extracted from two rats and placed in autoclaved
Dulbecco’s phosphate buffer saline (DPBS) (2.7 mM KCl, 1.5 mM KH2PO4, 136.9 mM NaCl,
8.9 mM Na2HPO4) on ice. DPBS was removed and the DRG were mechanically homogenized in
250 µl of ice cold homogenization buffer [0.3 M sucrose, 10 µl of 0.1 M PBS pH 7.4, 1 mM
EDTA, 1:100 protease inhibitor cocktail (Sigma, cat. P8340)] supplemented with 20 mM NEM
to prevent SUMO deconjugation. The homogenate was collected and nuclei and cellular debris
were pelleted by centrifugation at 14,000 RPM for 10 minutes at 4°C. The supernatant was
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retained and membranes were separated by ultracentrifugation in a tabletop ultracentrifuge at
40,000g for 90 min at 4°C. The supernatant was removed, and membranes were resuspended in
20 µl of denaturing buffer [1% SDS, 50 mM Tris-HCl pH 7.4, 5 mM DTT, 1:100 protease
inhibitor cocktail (Sigma, cat. P8340), 20 mM NEM]. The resuspended membrane pellet was
shaken for 1 hour at 4°C to aid in the resuspension of membrane proteins. The membrane
fraction was then brought to volume of 200 µl with dH2O to dilute the SDS prior to IPs. To
further denature proteins, the sample was heated at 95°C for 10 minutes. The boiled sample was
cooled on ice before addition of the IP antibody. ~1000 µg of protein was used for each IP with 5
µg of rabbit anti-HCN2 or 5 µg of normal IgG for negative controls. IPs were performed using
the Classic Magnetic IP/Co-IP Kit (Pierce, cat. 88804) according to the manufacturer’s
instructions. IP products were eluted in a volume of 50 µl.
2.4.9 Western Blot
An HCN2 IP and a negative IgG control from the same membrane preparation (see
above) were run side by side in sets of 3 on the same 12% SDS-polyacrylamide gel. After
electrophoresis, proteins were transferred from the gel for 2 h at 45 AMP to a PVDF membrane
(Immobilon-P, cat. #IPVH00010) using a semi-dry electroblotting system (OWL). The
membrane was cut into 3 pieces and each piece comprised one set of HCN2 and IgG IP products.
Membranes were blocked in 5% non-fat dry milk in TBS (50 mM Tris-HCl pH 7.4, 150 mM
NaCl) for 1 h at room temperature (RT). Blots were washed 1x for 10 minutes with TTBS
(TBS+ 0.1% Tween20), and then primary antibodies, prepared in 1% non-fat dry milk in TTBS,
were added and incubated overnight at 4°C. Each set was probed with a different antibody that
recognized HCN2, SUMO1 (Cell Signaling, 4930S, 1:1500) or SUMO2/3 (Abcam, ab3742,
1:750). Blots were washed 3x for 5 minutes in TTBS and then incubated with goat anti-rabbit
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alkaline phosphatase conjugated secondary antibody (Jackson ImmunoResearch, 1:4000),
prepared in 1% non-fat dry milk in TTBS, for 2 h with agitation at RT. Blots were washed 3x for
10 min with TTBS. The membranes were incubated with alkaline phosphatase substrate (Biorad)
for 5 minutes at RT, and then the membranes were exposed to X-ray film (MedSupply partners)
and the chemiluminescent signals were visualized with a Kodak X-Omat 2000A imager.
2.4.10 Statistics
All statistical analyses were performed using GraphPad Prism. Data were tested for
normality. Normal IHC data were analyzed with a one-way ANOVA followed by a Tukey’s
post-hoc test. Normal PLA data were analyzed with a paired t-test. Non-parametric data were
analyzed with Kruskal-Wallis (KW) for IHC or Wilcoxon matched-pairs signed rank tests for
PLA. All values are presented as the mean ± SEM. p<0.05 was considered statistically
significant.
2.5

Results

2.5.1 Inflammation increases the level of HCN2 expression and the number of cells
expressing HCN2
Previous studies examined the effects of cutaneous hindlimb inflammation in L5 DRG on day 7
post-CFA and in L4 DRG on days 1 and 4 post-CFA (Acosta et al., 2012; Weng et al., 2012).
This study examined the results of CFA-induced inflammation in L5 DRG on days 1 and 3 postCFA. In the experimental treatment group, CFA was injected into the right hindpaw of each
adult male Sprague-Dawley rat. In the control treatment group, rats were handled but not
injected. Animals were perfused on day 1 or 3 post-CFA injection/handling. L5 DRG were
dissected, cryosectioned (20 µm) and used in immunohistochemistry (IHC) experiments. The
specificity of the HCN2 antibody (anti-HCN2, Alomone Labs) was previously verified in a
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rigorous series of experiments (Acosta et al., 2012) and was confirmed here in a series of
preliminary IHC experiments using antibody that was pre-absorbed with the immunogen
provided by the manufacturer. Pre-absorption greatly diminished staining intensity (Figure 1A).
As described in Materials and Methods, raw images of IHC experiments (Figure 1B, left panel)
were processed, and HCN2-positive neurons were identified and circled (Figure 1B, right panel).
Cells were classified into three groups according to diameter: small (≤ 30 µm), medium (30 µm
< x <40 µm), and large (> 40 µm). HCN2 immunoreactivity (IR) was measured as the mean
pixel intensity for each cell and as the frequency of HCN2 expressing cells. The number of cells
expressing HCN2 was quantified for each of the three cell sizes by dividing the number of HCN2
positive cells in each size category by the total number of cells in the DRG section (HCN2positive and -negative) and multiplying by 100. This was termed frequency.
The mean pixel intensities measured on day 1 post-CFA were compared between control
and experimental DRG (Figure 2B). The average mean pixel intensity for small diameter neurons
in experimental animals significantly increased by ~50% in both contralateral (21.3 ± 1.4) and
ipsilateral (22.8 ± 1.7) relative to control DRG (14.9 ± 0.8). The average mean pixel intensity for
medium diameter neurons increased by ~40% in experimental (ipsilateral, 25.4 ± 2.6;
contralateral, 23.2 ± 1.5) relative to control DRG (18.0 ± 1.3). The increase was statistically
significant only for the ipsilateral DRG (Figure 2 legend). There were no significant differences
in the average mean pixel intensity between large diameter neurons (contralateral, 25.1 ± 2.1;
ipsilateral, 28.3 ± 3.8; control, 20.5 ± 2.2). A comparison of the mean frequency showed that
there were no significant differences between control and experimental animals or between
ipsilateral and contralateral DRG for any neuronal size class (Figure 2C). In general, ~55-65% of
all DRG neurons examined here expressed HCN2, and small-diameter neurons had the greatest

Regulation of HCN2 by SUMOylation

22

number of HCN2-positive cells (contralateral: small, 37.3 ± 4.8%; medium, 12.4 ± 1.8% large,
13.1 ± 2.0%) (ipsilateral: small, 34.1 ± 5.6%; medium, 13.8 ± 2.3%; large, 15.9 ± 4.4%) (control:
small, 22.3 ± 5.7%; medium, 14.2 ± 2.5%; large, 17.2 ± 1.9%).
The situation changed by day 3 post-CFA such that there was a significant increase in the
number but not intensity of cells expressing HCN2 (Figure 3). The average mean pixel
intensities were no longer significantly different for any size class (Figure 3B), although there
was still a slight elevation in contralateral (small, 21 ± 3.1; medium, 23.6 ± 3.7; large, 26.1 ± 4.7)
and ipsilateral DRG (small, 19.6 ± 2.5; medium, 22.4 ± 3.5; large, 24.8 ± 4.3) relative to control
DRG (small, 15 ± 1.9; medium, 16.9 ± 2.1; large, 18.7 ± 2.1). On the other hand, the number of
cells expressing HCN2 significantly increased in small and medium but not large diameter
neurons in experimental relative to control animals (Figure 3C). Mean frequency in both
contralateral (small, 35.8 ± 8.3%; medium, 17.2 ± 1.7%) and ipsilateral DRG (small, 30.6 ±
3.5%; medium, 15.8 ± 1.4%) were significantly increased relative to control DRG (small, 11.9 ±
2.4%; medium, 9.5 ± 0.7%), but were not significantly different from one another.
In sum, unilateral hindpaw inflammation initially produced a significant bilateral increase
in HCN2 protein expression in small diameter neurons. CFA-induced inflammation also
produced a significant ipsilateral increase in medium diameter neurons. As inflammation
progressed, expression levels returned back toward normal, but the number of small and medium
diameter cells expressing HCN2 increased bilaterally.
2.5.2 HCN2 is SUMOylated in the rat DRG
SUMOylation of HCN2 channels has never been examined in DRG neurons. To determine if
HCN2 channels were SUMOylated in DRG neurons, denaturing immunoprecipitation (IP)
experiments were performed using DRG membrane preparations and an antibody against HCN2
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followed by western blot experiments with antibodies against HCN2, SUMO2/3 and SUMO1.
The experiment was repeated 3 times (i.e. 6 rats, see Materials and Methods). A representative
experiment shows that all 3 antibodies recognized the same appropriately sized ~100kD band
(Figure 4). This band was not observed in IP experiments using a non-specific rabbit IgG on the
same membrane preparation. In order to prevent non-covalent interactions between proteins, i.e.
co-IP, the membrane preparations were denatured with a high concentration of SDS (1%) and
high heat treatment (95°C for 10min) prior to the IPs (see Materials and Methods). These data
indicate that SUMO1 and SUMO2/3 are covalently linked to HCN2

-subunits in the rat DRG.

Next, in situ proximity ligation assays (PLA) were used to examine HCN2 channel
SUMOylation in individual DRG neurons. Preliminary pre-absorption experiments on
cryosectioned DRG confirmed the specificities of the SUMO1 (anti-SUMO1) and SUMO2/3
(anti-SUMO2/3) antibodies (Figure 5A). HCN2 channel SUMOylation was examined using antiHCN2 and anti-SUMO2/3 in PLA on cryosectioned DRG (experimental). Primary antibodies
were omitted in control PLA. SUMOylated HCN2 channels appeared as fluorescent puncta in
confocal optical sections (Figure 5B, upper panels). Punctum area and intensity varied, which
may reflect differences in the number of HCN2 channels represented by a punctum, e.g. solitary
vs. clustered channels, and/or the extent of their SUMOylation. Puncta number and punctum
mean pixel intensity were used as measures of the number of SUMOylated channels and the
extent of channel SUMOylation, respectively. To measure HCN2 channel SUMOylation in a
single cell, a confocal projection representing 5, ~1 µm optical sections from the center of a cell
was obtained. Note that this represents ~ 1/4 (small) to 1/8 (large) of the volume of a neuron and
that surface sections will be excluded, i.e., all plasma membrane staining lies along the perimeter
of the cell. A cell was outlined and automatically thresholded to eliminate background (Figure
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5B, bottom panels). ImageJ was then used to measure the area of the cell as well as the number
and intensity of puncta from within the circled region. Control and experimental PLA were
performed on alternating sections of L5 DRG. DRG from 3 animals were analyzed. Results
showed significantly more puncta/µm2 in experimental vs. control treatment groups (Figure 5C).
These data indicated that HCN2 channels were decorated with SUMO2/3 in rat L5 DRG and that
this method could be used to examine HCN2 channel SUMOylation in individual neurons.
2.5.3 Significantly more HCN2 SUMO2/3 conjugation is observed in small diameter
neurons from ipsilateral DRG on day 1 but not on day 3 post-CFA
In order to test if HCN2 channels were hyper-SUMOylated during CFA-induced inflammation,
CFA was injected into the right hindpaw of adult male rats. Animals were perfused 1 or 3 days
post-CFA. Bi-lateral L5 DRG were dissected and cryosectioned. In situ PLA was performed on
the cryosections using anti-HCN2 and anti-SUMO2/3. Control animals were handled but not
injected. HCN2 channels were decorated with SUMO2/3 in small, medium and large neurons
from ipsilateral and contralateral DRG 1 day post-CFA (Figure 6A). The number of puncta per
µm2 was determined for the 3 size classes of neurons. Comparisons of control and experimental
animals showed no significant differences and are not reported here. On the other hand, paired
comparisons between contralateral and ipsilateral DRG from the same experimental animal
revealed significant differences. Most likely, differences were revealed in the latter analyses
because biological variability was reduced by intra-animal comparison.
A significant ~25% increase in puncta number was observed in small neurons from
ipsilateral relative to contralateral DRG (Figure 6B). No significant differences were observed in
medium or large diameter neurons in contralateral vs. ipsilateral DRG (Figure 6B). Paired t-tests
on left vs. right DRG in the control treatment group indicated no significant differences (small,
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0.24 ± 0.04 vs. 0.23 ± 0.03, p=0.5389; medium, 0.23 ± 0.04 vs. 0.21 ± 0.06, p=0.6006; large,
0.26 ± 0.03 vs. 0.23 ± 0.04, p=0.6340; n=3 animals). Punctum intensity was divided by punctum
area to obtain the mean pixel intensity per punctum, here termed puncta intensity. The average
puncta intensity was calculated for each cell. Average puncta intensity was not significantly
different between contralateral vs. ipsilateral DRG neurons for any size class (Figure 6C).
Control animals showed no differences between left vs. right DRG (small, 47.82 ± 2.74 vs. 41.80
± 4.32, p=0.25; medium, 47.72 ± 2.79 vs. 42.68 ± 4.77, p=0.1694; large, 48.96 ± 2.19 vs. 42.98 ±
5.32, p=0.2730; n=3).
Analyses were performed for animals perfused at 3 days post-CFA (Figure 7A). There
were no significant differences in HCN2-SUMO2/3 puncta number (Figure 7B) or intensity
(Figure 7C) between contralateral vs. ipsilateral DRG neurons from experimental animals for
any neuronal size class. There were also no significant differences between left vs. right DRG in
the control treatment group for either puncta number (small, 0.38 ± 0.08 vs. 0.39 ± 0.11,
p=0.8946; medium, 0.43 ± 0.11 vs. 0.36 ± 0.12, p=0.2152; large, 0.50 ± 0.10 vs. 0.41 ± 0.11,
p=0.0708; n=4) or puncta intensity (small, 71.23 ± 17.97 vs. 61.01 ± 12.95, p=0.1466; medium,
69.65 ± 16.31 vs. 61.14 ± 12.65, p=0.1181; large, 69.74 ± 17.88 vs. 61.03 ± 12.82, p=0.1987;
n=4).
In sum, the number of HCN2 channels decorated with SUMO2/3 was transiently
increased by ~25% in small neurons from ipsilateral relative to contralateral DRG on day 1 but
not 3 post-CFA. There were no significant changes in the extent of channel SUMOylation.
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2.5.4 Conjugation of SUMO1 to HCN2 channels was reduced in medium and large diameter
DRG neurons on 1 day post-CFA, and increased in small neurons on day 3 post-CFA
PLA experiments were repeated for experimental and control animals except that antiSUMO1 was used. HCN2 channels decorated with SUMO1 were observed on day 1 post-CFA
(Figure 8). Paired t-tests indicated that the mean number of HCN2-SUMO1 puncta was not
significantly different in small neurons from contralateral vs. ipsilateral DRG, but puncta number
was significantly reduced by ~30% in medium and large diameter neurons from ipsilateral
relative to contralateral DRG (Figure 8B). There were no significant differences in mean puncta
number between left vs. right DRG from control animals for any cell size (small, 0.35 ± 0.06 vs.
0.34 ± 0.09, p=0.7672; medium, 0.31 ± 0.05 vs. 0.27 ± 0.08, p=0.3750; large, 0.39 ± 0.12 vs.
0.31 ± 0.07, p=0.2184; n=4). There were no significant differences in puncta intensity between
contralateral vs. ipsilateral DRG for any neuronal size (Figure 8C). There were no significant
differences in puncta intensity for left vs. right DRG from control animals (small, 55.22 ± 10.11
vs. 51.25 ± 7.35, p=0.6250; medium, 55.83 ± 10.77 vs. 53.47 ± 6.94, p=0.8750; large, 58.5 ±
11.15 vs. 55.65 ± 5.70, p>0.9999; n=4).
SUMO1 conjugation to HCN2 channels was examined 3 days post-CFA (Figure
9). HCN2-SUMO1 puncta number was significantly increased by ~27% in small neurons from
ipsilateral relative to contralateral DRG (Figure 9B). There were no significant differences in
medium or large diameter neurons in ipsilateral relative to contralateral DRG (Figure 9B). There
were no significant differences in puncta number for left vs. right DRG from control animals
(small, 0.28 ± 0.02 vs. 0.28 ± 0.08, p=0.9861; medium, 0.23 ± 0.01 vs. 0.27 ± 0.10, p=0.7612;
large, 0.31 ± 0.03 vs. 0.33 ± 0.10, p=0.8797; n=3). As in all other cases, there were no significant
differences in puncta intensity for contralateral vs. ipsilateral DRG for any cell size (Figure 9C).
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Control animals also showed no differences in left vs. right DRG puncta intensity (small, 65.55 ±
16.13 vs. 48.64 ± 4.701, p=0.3539; medium, 71.14 ± 23.03 vs. 48.51 ± 3.7, p=0.3559; large,
67.96 ± 18.46 vs. 50.43 ± 2.37, p=0.3077; n=3).
In sum, SUMO conjugation to HCN2 channels was increased in small diameter
neurons from ipsilateral DRG on days 1 and 3 post-CFA. Dynamic changes varied with the
SUMO isoform. Whereas conjugation to HCN2 channels with SUMO2/3 increased on day 1,
conjugation with SUMO 1 increased on day 3. In medium and large diameter neurons, SUMO1
conjugation to HCN2 channels was transiently reduced on day 1 post-CFA.
2.6

Discussion
An HCN2-mediated increase in Ih is necessary for mechanical hyperalgesia experienced

during persistent inflammation. The present study investigated how HCN2 channels in L5 DRG
were altered during early stages of inflammation. The major finding of this study was that an
increase in HCN2 protein expression was not sufficient for mechanical hyperalgesia. Moreover,
HCN2 channel SUMOylation was significantly increased in small diameter neurons and
decreased in medium and large diameter neurons in ipsilateral relative to contralateral DRG.
2.6.1 HCN2 protein expression and SUMOylation of HCN2 channel complexes are
increased in small diameter neurons during CFA-induced inflammation
Persistent inflammation is thought to be a primary mechanism whereby an acute injury leads to a
chronic pain state (Dubin and Patapoutian 2010; Emery et al., 2012; Pinho-Ribeiro et al., 2017;
Tsantoulas et al., 2016; Xu and Yaksh 2011). CFA administration elicits persistent inflammation
(Millan et al., 1988; Stein et al., 1988). In rats, a unilateral, intraplantar CFA injection
significantly reduces the mechanical force necessary to produce ipsilateral paw withdrawal 1 to
14 days after inflammation. The observed mechanical hyperalgesia is not present in the
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contralateral paw (Goff et al., 1998; Hurley and Hammond 2000; Millan et al., 1988; Schnorr et
al., 2014; Stein et al., 1988; Weng et al., 2012). The cutaneous inflammatory response is resolved
by 17-21 days (Li et al., 2005). Inflammation alters several ionic currents in sensory neurons,
including Ih, and specifically increases the excitability of C-fiber nociceptors (Herrmann et al.,
2017; Pace et al., 2018; Takeda et al., 2014; Weng et al., 2012; Zemel et al., 2018). Ih increases
the excitability of DRG sensory neurons by limiting membrane hyperpolarization and facilitating
depolarization (Yagi and Sumino 1998). CFA-induced inflammation triggers an increase in the
activation kinetics and maximal conductance of nociceptor Ih (Djouhri et al., 2015). Injections of
pharmacological agents to block Ih as early as 1 day after CFA-induced inflammation prevent
hyperalgesia (Schnorr et al., 2014; Weng et al., 2012).
The mechanism(s) producing a CFA-induced increase in nociceptor Ih is unknown. In rat
DRG sensory neurons, Ih is mediated largely by HCN isoforms 1 and 2, and to a lesser extent,
HCN3 (Gao et al., 2012; Kouranova et al., 2008; Weng et al., 2012), which can form homo- and
hetero-tetramers. Channel complexes can also contain auxiliary subunits (Piskorowski et al.,
2011; Santoro et al., 2011; Santoro et al., 2009; Saponaro et al., 2014). Genetic ablation of
HCN2 from DRG sensory neurons attenuated mechanical hyperalgesia measured on day 3 postCFA (Schnorr et al., 2014). Hindlimb inflammation elicited a transient increase HCN2 IR in
small diameter neurons in ipsilateral rat L4 DRG on day 1 but not day 4 post-CFA, relative to
uninjected controls (Acosta et al., 2012). A significant decrease was also observed in large
diameter neurons on day 4 post-CFA (Acosta et al., 2012). A second study examined the effects
of hindlimb inflammation on ipsilateral L5 DRG neurons 7 days post-CFA; it showed a
significant increase in HCN2 IR in small diameter neurons and a significant increase in the
number of small and medium diameter neurons expressing HCN2, but no change in HCN1 or
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HCN3 expression relative to uninjected controls (Weng et al., 2012). The current study shows a
significant bilateral increase in HCN2 IR in small and medium diameter L5 DRG neurons on day
1 post-CFA relative to uninjected controls. In addition, there is a significant bilateral increase in
the number of cells expressing HCN2 on day 3 post-CFA. The bilateral changes were
unexpected since CFA injection was unilateral. Unilateral peripheral nerve damage can result in
unilateral hyperalgesia but bilateral changes in DRG cytokine and cytokine receptor mRNA and
protein expression (Brazda et al., 2009; Dubovy et al., 2013; Jancalek et al., 2010; Jancalek et al.,
2011) and NaV1.8 mRNA (Oaklander and Belzberg 1997). Such changes are thought to be due
to a generalized inflammatory response. Several mechanisms could underlie bilateral effects
(Koltzenburg et al., 1999).
Our data suggest that an increase in HCN2 protein expression is not sufficient for
mechanical hyperalgesia because, unilateral injection of CFA produces unilateral hyperalgesia
(Hurley and Hammond 2000; Stein et al., 1988) but a bilateral increase in HCN2 protein
expression (Figures 2 & 3). Altered expression of additional ion channels and/or other proteins
may be necessary for hyperalgesia (Pace et al., 2018). Alternatively, additional post-translational
modifications to HCN2 channels may be required. Recent studies demonstrated that enhanced
ion channel SUMOylation can contribute to hyperalgesia in models of chronic pain (FrancoisMoutal et al., 2018; Moutal et al., 2017; Wang et al., 2018a). Post-translational SUMOylation
can regulate ion channel biophysical properties, trafficking and surface expression (Benson et al.,
2007; Chamberlain et al., 2012; Dai et al., 2009; Dustrude et al., 2016; Martin et al., 2007;
Parker et al., 2017; Plant et al., 2010; Plant et al., 2016; Plant et al., 2012; Qi et al., 2014; Rajan
et al., 2005; Steffensen et al., 2018; Wang et al., 2018b; Welch et al., 2019; Xiong et al., 2017).
Our data indicate that unilateral CFA injection produces unilateral hyper-SUMOylation of HCN2
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in small diameter neurons from L5 DRG. HCN2 SUMOylation produces an increase in channel
surface expression and Ih in a heterologous expression system (Parker et al., 2017), but the effect
of the enhanced DRG HCN2 SUMOylation observed here is unknown.
Because HCN2

-subunits are SUMOylated in the DRG (Figure 4), the most

parsimonious interpretation of the PLA experiments is that SUMOylation of HCN2

-subunits is

enhanced during inflammation. However, in order to produce a fluorescent punctum in a PLA,
the HCN2 and SUMO proteins need to be within 40nM of one another so that their antibodies
can interact to generate a punctate fluorescent signal. HCN channels can exist as heterotetramers
in multiprotein complexes with auxiliary proteins like TRIP8b (Santoro et al., 2009) and MINT
(Kimura et al., 2004), which also have predicted SUMOylation sites. This means that the
increase in PLA puncta number could also represent increased SUMOylation of other HCN
isoforms and/or auxiliary subunits that make-up the HCN2 channel complex. Indeed, it is well
documented that a cell stressor can evoke group SUMOylation, whereby several proteins in a
physically linked group are non-specifically SUMOylated, as opposed to targeting one specific
protein within the group (Jentsch and Psakhye 2013).
The increase in SUMOylated HCN2 channel complexes is a modest ~27%, but it is fairly
common for low levels of SUMOylation to exert substantial regulatory effects (Benson et al.,
2007; Flotho and Melchior 2013). Nevertheless, there are examples of much greater increases in
SUMOylation, for example, CRMP2 SUMOylation in the sciatic nerve, spinal dorsal horn and
glabrous skin appears to increase by as much as ~300% in a rat model of neuropathic pain
(Moutal et al., 2017). Small diameter DRG neurons can be classified into at least six cell types
(Li et al., 2016; Usoskin et al., 2015), and it is possible that a specific nociceptor cell type
representing a small fraction of the population shows a much larger increase in HCN2
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SUMOylation. Since the cell type(s) exhibiting the CFA-induced enhancement of HCN2 protein
expression and HCN2 channel SUMOylation were not identified, we cannot conclude that
increased expression and SUMOylation are coincident in the same cell or that the inflammationinduced increase in nociceptor Ih depends upon a 2-step process.
There are four SUMO isoforms and three were examined in this study. Conjugation of
SUMO2/3 vs. SUMO1 to HCN2 channel complexes was differentially regulated as inflammation
progressed: SUMO2/3 but not SUMO1 conjugation to HCN2 channels was significantly
increased on day 1 post-CFA, and the opposite was true on day 3 post-CFA. The sole SUMO
conjugating enzyme, ubc9, does not show a preference for SUMO isoforms and interacts with a
similar affinity for all isoforms (Knipscheer et al., 2007), but the SENP family of SUMO
isopeptidases that mediate SUMO deconjugation can exhibit SUMO isoform specificity and can
be differentially localized by post-translational modification (Kunz et al., 2018). Likewise,
diverse E3 proteins that stabilize interactions between ubc9 and its targets can also exhibit
SUMO isoform specificity (Cappadocia et al., 2015; Koidl et al., 2016; Tatham et al., 2005).
Together, these data support the emerging ideas that inflammatory mediators regulate the
nociceptor SUMOylation machinery and that this regulation may effect alterations in multiple
ionic conductances during nociceptor sensitization.
2.6.2 SUMOylation of HCN2 channel complexes is decreased in medium and large diameter
neurons during CFA-induced inflammation
SUMO1 conjugation to HCN2 channel complexes was transiently decreased in medium
and large diameter neurons from ipsilateral L5 DRG on day 1 of inflammation. This regulation
could potentially contribute to hyperalgesia which peaks on day 1 (Millan et al., 1988; Stein et
al., 1988). Medium and large neurons could contribute directly to hyperalgesia as nociceptors
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(Dubin & Patapoutian, 2010; Nagi et al., 2019), or they could indirectly influence nociceptor
activity through presynaptic mechanisms and/or other circuit effects (Braz, Solorzano, Wang, &
Basbaum, 2014; Guo & Hu, 2014; Mendell, 2014). It will be important to identify these neurons
and how HCN2 channel deSUMOylation regulates their activity.

Figure 2-1 Validation of anti-HCN2 and quantification of HCN2 positive cells.

A) Representative IHC. Experiments using antibody and pre-absorbed antibody show antiHCN2 specificity. Scale bars are 100 m. B) Representative analysis. Sections show cells
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before and after thresholding. Cells having an obvious nucleus and plasma membrane, and
therefore meeting the criteria for analysis, are circled.
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Figure 2-2 CFA-induced inflammation alters HCN2 protein expression on 1 day postCFA.
A) Representative images of HCN2 IR in contralateral and ipsilateral L5 sections 1 day
post-CFA injection. Scale bars are 100 m. B) HCN2 expression is elevated in experimental
compared to control DRG. Average mean pixel intensities + SEMs are plotted for three size
classes of DRG neurons. A one way ANOVA with a Tukey’s post-hoc test that makes all
possible comparisons shows HCN2 IR is significantly elevated in small cells for experimental vs.
control treatment groups (F(2,17)=8.468; p=0.0028). Asterisks indicate which two-way
comparisons were significant. A one way ANOVA with a Tukey’s post-hoc shows HCN2 IR is
significantly elevated in medium cells for ipsilateral vs. control treatment groups (F(2,17)=3.748;
p=0.0448). Asterisks indicate which pairwise comparisons were significant: *, p<0.05; **,
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p<0.01. A one way ANOVA shows that HCN2 IR was not significantly different between large
cells from experimental and control DRG (F(2,17)=1.794; p=0.1963). C) HCN2 frequency is
unaltered 1 day post-CFA injection. Bar plots of the frequency of HCN2 positive neurons in
each size category ([HCN2-expressing cells per category ÷ total number of cells in all categories]
x 100). Statistical tests show there were no significant differences between experimental and
control animals for any cell type (small; KW(2,17)=3.603; p=0.1682; medium; F(2,17)=0.1860;
p=0.8317; large; KW(2,17)=1.999; p=0.3824).
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Figure 2-3 HCN2 protein expression is altered on day 3 post-CFA.
A) Representative images of HCN2 IR in contralateral and ipsilateral L5 sections 3 days
post-CFA. Scale bars are 100 m. B) The intensity of HCN2 IR is unaltered 3 days postCFA. Bar plots of mean pixel intensity. One way ANOVAs show no significant differences
between treatment groups for any size category (small; F(2,15)=1.893; p=0.1849; medium;
F(2,15)=1.667; p=0.2220; large; F(2,15)=1.499; p=0.2550). C) HCN2 frequency is
significantly increased in small and medium diameter neurons in experimental compared
to control animals. Bar plots of the frequency of HCN2 IR in each size class ([HCN2expressing cells per category ÷ total number of cells in all categories] x 100). A one way
ANOVA with a Tukey’s post-hoc test shows HCN2 frequency is significantly elevated in small
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cells for experimental vs. control treatment groups (F(2,15)=8.022; p =0.0043). Asterisks
indicate which two-way comparisons were significant. A one way ANOVA with a Tukey’s posthoc test shows HCN2 frequency is significantly elevated in medium cells for experimental vs.
control treatment groups (F(2,15)=13.51; p=0.0004). Asterisks indicate significant differences in
pairwise comparisons: *, p<0.05; **, p<0.01; ***, p<0.001. A Kruskal-Wallis test shows HCN2
frequency is not significantly different between large cells for experimental vs. control treatment
groups (KW(2,15)=3.058; p=0.2251).
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Figure 2-4 HCN2 is SUMOylated in rat DRG.
Denaturing immunoprecipitation (IP) experiments were performed on a DRG membrane
preparation with an antibody against HCN2 or IgG (control). IP products from 1 membrane
preparation were run in triplicate on an SDS-polyacrylamide gel followed by western blotting
(WB). The blot was cut into 3, and probed for HCN2, SUMO2/3 and SUMO1. The experiment
was repeated using 3 different DRG membrane preparations. A representative result from one
experiment is shown. All 3 WB antibodies recognized the same ~100kD protein in the HCN2 IP
product but not the IgG IP product. The data indicate that SUMO1 and SUMO2/3 are covalently
linked to HCN2
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Figure 2-5 Measuring HCN2 channel SUMOylation.
A) Verification of SUMO antibodies. Antibodies were (right) or were not (left) preabsorbed
with the corresponding peptide for SUMO2/3 (upper panel) or SUMO1 (lower panel). SUMO is
predominately expressed in nuclei. Note the loss of nuclear staining following preabsorption, e.g.
white arrows in bottom panel. Scale bars are 100 µm. B) Method for quantifying HCN2
channel SUMOylation. In situ PLA was performed on DRG cryosections with (experimental)
or without (control) antibodies against SUMO2/3 and HCN2. Upper panel shows a 5µm
projection of confocal optical slices through representative cells from control and experimental
treatment groups. Each image represents a projection of 5 slices in continuous succession that
together encompass the center of the cell. Each optical section is 0.9 µm with a z-stack interval
of 1 µm. Note that the red puncta indicating SUMOylated HCN2 channels were largely absent
when antibodies were omitted. Scale bar is 10 µm. The cells were circle and thresholded, and the
resulting image is shown in the lower panel. Black puncta within the circled region were counted
using the analyze particle tool on imageJ and normalized by the area (µm2) of the circle. Note
that all black puncta, regardless of size were counted. C) HCN2 channels are SUMOylated in
DRG neurons. Plots of puncta per µm2 show there are significantly more puncta when primary
antibodies for HCN2 and SUMO2/3 were included (0.08 ± 0.01 vs. 0.16 ± 0.02, p=0.0149,
paired t-test, n=3, 70 and 62 cells analyzed in total). The lines indicate that the cells were from
the same experiment, i.e. alternate sections from a single DRG on the same slide receiving the
same PLA reagents and treated in an identical fashion.
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Figure 2-6 SUMO2/3 conjugation to HCN2 channels is increased in small diameter
neurons from ipsilateral relative to contralateral DRG at 1 day post-CFA.
A) Representative PLA. Scale bars are 25 µm. Note that this image provides an overview, but
for the purpose of quantification, individual projections were made for each cell, e.g. Figure 4B.
B) Plots of mean number of puncta/µm2 for all DRG from 6 CFA treated animals on day 1
post-CFA. The number inside the bar represents the total number of cells analyzed. Inset: Each
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line compares the means for contralateral and ipsilateral DRG from one animal. Paired t-tests
indicate the number of puncta significantly increased for small but not medium or large neurons
in ipsilateral compared to contralateral DRG (small, 0.23 ± 0.02 vs. 0.29 ± 0.04, p=0.0499;
medium, 0.24 ± 0.02 vs. 0.26 ± 0.02, p=0.2120; large, 0.26 ± 0.03 vs. 0.31 ± 0.04, p=0.4259. C)
Plots of mean puncta intensity on day 1 post-CFA. Paired t-tests indicate mean puncta
intensities were not significantly different between ipsilateral and contralateral DRG for any size
category (small, 44.47 ± 3.1 vs. 41.86 ± 3.9, p=0.4495; medium, 43.06 ± 2.5 vs. 42.43 ± 4.1,
p=0.8503; large, 43.74 ± 3.1 vs. 44.51 ± 4.8, p=0.8518).
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Figure 2-7 SUMOylation of HCN2 channels by SUMO2/3 does not change 3 days postCFA.
A) Representative PLA. Scale bars are 25 µm. Note that this image provides an overview, but
for the purpose of quantification, individual projections were made for each cell, e.g. Figure 4B.
B) Plots of mean number of puncta/µm2 for all DRG from 7 CFA treated animals on day 3
post-CFA. The number inside the bar represents the total number of cells analyzed. Inset: Each
line compares means for contralateral and ipsilateral DRG from one animal. Wilcoxon matched-
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pair tests indicate no significant difference in puncta number for small, medium or large diameter
cells (small, 0.32 ± 0.05 vs. 0.35 ± 0.04, p=0.375; medium, 0.31 ± 0.07 vs. 0.32 ± 0.06,
p=0.5781; large, 0.35 ± 0.05 vs. 0.36 ± 0.06, p=0.8125). C) Plots of mean puncta intensity on
day 3 post-CFA. Paired t-tests indicate mean puncta intensities were not significantly different
for any size category in ipsilateral compared to contralateral DRG (small, 43.13 ± 3.73 vs. 44.4 ±
3.56, p=0.731; medium, 43.4 ± 3.98 vs. 44.78 ± 3.45, p=0.7087; large; 44.35 ± 4.04 vs. 46.75 ±
3.36, p=0.5670).
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Figure 2-8 HCN2 channel SUMOylation by SUMO1 is diminished in medium and large
diameter neurons from ipsilateral relative to contralateral DRG at 1 day post-CFA.
A) Representative PLA. Scale bars are 25 µm. Note that this image provides an overview, but
for the purpose of quantification, individual projections were made for each cell, e.g. Figure 4B.
B) Plots of mean number of puncta/µm2 for all DRG from 6 CFA treated animals on day 1
post-CFA. The number inside the bar represents the total number of cells analyzed. Inset: Each
line compares means for contralateral and ipsilateral DRG from one animal. Paired t-tests
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indicate medium and large diameter cells contain significantly fewer puncta in the ipsilateral
DRG relative to the contralateral DRG (small, 0.33 ± 0.05 vs. 0.27 ± 0.03, p=0.2058; medium,
0.34 ± 0.05 vs. 0.24 ± 0.03, p=0.0480; large, 0.37 ± 0.05 vs. 0.26 ± 0.02, p=0.0238). C) Plots of
mean puncta intensity on day 1 post-CFA. Paired t-tests indicate mean puncta intensities were
not significantly different for any size category in ipsilateral compared to contralateral DRG
(small, 44.68 ± 4.03 vs. 41.48 ± 2.66, p=0.5986; medium, 42.7 ± 3.24 vs. 45.65 ± 4.06,
p=0.6299; large, 44.44 ± 3.68 vs. 46.39 ± 4.27, p=0.7631).
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Figure 2-9 HCN2 channel SUMOylation by SUMO1 is increased in small neurons from
ipsilateral relative to contralateral DRG at 3 days post-CFA.
A) Representative PLA. Scale bars are 25 µm. Note that this image provides an overview, but
for the purpose of quantification, individual projections were made for each cell, e.g. Figure 4B.
B) Plots of mean puncta/µm2 for all DRG from 6 CFA treated animals on day 3 post-CFA.
The number inside the bar represents the total number of cells analyzed. Inset: Each line

Regulation of HCN2 by SUMOylation

48

compares means for contralateral and ipsilateral DRG from one animal. Significantly more
puncta were observed in ipsilateral relative to contralateral DRG as indicated by paired t-tests or
non-parametric alternative* (small, 0.25 ± 0.03 vs. 0.32 ± 0.03, p=0.0285; medium, 0.29 ± 0.05
vs. 0.25 ± 0.06, p=0.4310; large*, 0.32 ± 0.03 vs. 0.28 ± 0.06, p=0.5625). C) Plots of mean
puncta intensity on day 3 post-CFA. Paired t-tests indicate mean puncta intensities were not
significantly different for any size category in ipsilateral compared to contralateral DRG (small,
46.14 ± 3.0 vs. 46.08 ± 1.41, p=0.9826; medium, 44.58 ± 4.12 vs. 46.45 ± 1.32, p=0.6612; large,
44.99 ± 3.38 vs. 48.35 ± 1.27 p=0.2758).
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Abstract
Nociceptor sensitization following nerve injury or inflammation leads to chronic pain. An

increase in the nociceptor hyperpolarization-activated current, Ih, is observed in many models of
pathological pain. Pharmacological blockade of Ih prevents the mechanical and thermal
hypersensitivity that occurs during pathological pain. Alterations in the Hyperpolarizationactivated Cyclic Nucleotide-gated ion channel 2 (HCN2) mediate Ih-dependent thermal and
mechanical hyperalgesia. Limited knowledge exists regarding the nature of these changes during
chronic inflammatory pain. Modifications in HCN2 expression and post-translational
SUMOylation have been observed in the Complete Freund’s Adjuvant (CFA) model of chronic
inflammatory pain. Intra-plantar injection of CFA into the rat hindpaw induces unilateral
hyperalgesia that is sustained for up to 14 days following injection. The hindpaw is innervated by
primary afferents in lumbar DRG, L4-6. Adjustments in HCN2 expression and SUMOylation
have been well-documented for L5 DRG during the first 7 days of CFA-induced inflammation.
Here, we examine bilateral L4 and L6 DRG at day 1 and day 3 post-CFA. Using L4 and L6 DRG
cryosections, HCN2 expression and SUMOylation were measured with immunohistochemistry
and proximity ligation assays, respectively. Our findings indicate that intra-plantar injection of
CFA elicited a bilateral increase in HCN2 expression in L4 and L6 DRG at day 1, but not day 3,
and enhanced HCN2 SUMOylation in ipsilateral L6 DRG at day 1 and day 3. Changes in HCN2
expression and SUMOylation were transient over this time course. Our study suggests that
HCN2 is regulated by multiple mechanisms during CFA-induced inflammation.
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Introduction

Persistent inflammation and/or nerve injury can lead to chronic pain. This debilitating condition
is characterized by allodynia (pain in response to non-noxious stimuli), hyperalgesia (increased
sensitivity to noxious stimuli), and spontaneous painful and/or burning sensations in the absence
of stimuli (Dubin & Patapoutian, 2010; Emery, Young, & McNaughton, 2012; Kuner & Flor,
2016; Pinho-Ribeiro, Verri, & Chiu, 2017; Tsantoulas, Mooney, & McNaughton, 2016; Xu &
Yaksh, 2011). Chronic pain is underpinned by widespread reorganization of the pain circuitry,
including changes to component neurons. While component neurons throughout the pain circuit
can be altered (Boadas-Vaello, Homs, Reina, Carrera, & Verdu, 2017; Du, Wang, Cui, He, &
Ruan, 2013a, 2013b), here we focus specifically upon nociceptors.
Nociceptors are peripheral sensory neurons that initiate pain signalling upon detecting
noxious temperatures, pressures and chemicals (Dubin & Patapoutian, 2010). Nociceptor somata
are located in the Dorsal Root Ganglia (DRG) and trigeminal ganglia. A single process projects
from the soma; it bifurcates, and one process extends to the periphery and the other innervates
the central nervous system. Nociceptors are functionally classified by their conduction velocities:
C-fibers have small-diameter, unmyelinated axons; A𝛿 nociceptors have small to medium
diameter, lightly myelinated axons; and, there is also a class of A𝛽 nociceptors that have larger
diameter myelinated axons (Djouhri & Lawson, 2004; Nagi et al., 2019). The range of
conduction velocities for each of these 3 classes varies with the species, but for the sake of
comparison, the peak conduction velocities for C-, A𝛿- and A𝛽-fibers in a typical guinea pig
compound action potential are approximately 0.6m/s, 3.3m/s and 9.6m/s, respectively (Djouhri &
Lawson, 2004). Neurons within each class are functionally subdivided according to their
threshold to noxious chemical, mechanical, and thermal stimuli. Recently, unbiased RNA
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sequencing approaches have been included in classification schemes (C. L. Li et al., 2016;
Usoskin et al., 2015), and several principal nociceptor cell types have been identified, each with
a unique transcriptome, size and sensory function.
Nociceptors become hyper-excitable in chronic pain states elicited by nerve damage
(neuropathic pain) and/or persistent, unresolved inflammation (inflammatory pain). This
sensitization not only changes nociceptor responses to noxious and non-noxious stimuli, but also
drives pathological changes to CNS components of the pain circuitry. Nociceptor sensitization is
due, in part, to persistent alterations in a number of ionic currents that act to reduce threshold and
increase cell excitability (Berta et al., 2017; Gold & Gebhart, 2010; Pace et al., 2018; Reichling
& Levine, 2009; Tibbs et al., 2016; Zemel, Ritter, Covarrubias, & Muqeem, 2018). The
hyperpolarization-activated, non-specific cation current, Ih, is a slowly depolarizing current that
functions to enhance nociceptor excitability (Yagi & Sumino, 1998). Under normal conditions, Ih
plays a limited role in pain transmission, and pain thresholds are largely unaffected by
pharmacological inhibition or genetic ablation of Ih (Emery et al., 2011; Schnorr et al., 2014;
Takasu, Ono, & Tanabe, 2010). However, during sensitization, Ih transitions into a pivotal role in
pain signalling. In multiple models of chronic pain, nociceptor Ih amplitude is increased, and
pharmacological agents that block Ih reduce nociceptor excitability and return pain thresholds to
baseline (Chaplan et al., 2003; Dalle & Eisenach, 2005; Lee, Chang, Sorkin, & Chaplan, 2005;
Luo et al., 2007; Richards & Dilley, 2015; Schnorr et al., 2014; Sun, Xing, Tu, Han, & Wan,
2005; Tibbs et al., 2016; Tsantoulas et al., 2017; Tsantoulas et al., 2016; X. Wang et al., 2016;
Weng et al., 2012; Yao, Donnelly, Ma, & LaMotte, 2003). In addition, blocking Ih during
chronic pain can also reduce the release of inflammatory mediators and glial activation (Huang,
Zhang, & Huang, 2019).
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The family of hyperpolarization activated, cyclic nucleotide gated ion channels, isoforms
1-4 (HCN 1-4), mediate Ih. These pore-forming 𝛼-subunits are assembled into homo- and heterotetrameric channels that are largely permeable to K+ and Na+, and may also display a small
permeability for Ca2+ (Sartiani, Mannaioni, Masi, Novella Romanelli, & Cerbai, 2017; WahlSchott & Biel, 2009). Channels open upon hyperpolarization, but isoforms differ in their
activation kinetics: HCN1 is the fastest and HCN4 is the slowest. All isoforms possess a cyclic
nucleotide binding domain (CNBD), which when bound by cAMP shifts the voltage dependence
of activation to more positive potentials. Isoforms show varying degrees of cAMP sensitivity,
with HCN2 and HCN4 exhibiting the largest depolarizing shift in voltage dependence upon
binding cAMP. Homo- and hetero-tetrameric channels composed largely of HCN1 and HCN2,
and to a lesser extent, HCN3, conduct nociceptor Ih (Gao et al., 2012; Kouranova, Strassle, Ring,
Bowlby, & Vasilyev, 2008; Weng et al., 2012).
Studies utilizing genetic ablation of specific HCN isoforms have begun to identify
isoform-specific contributions to chronic pain. HCN1 contributes to cold allodynia during
neuropathic pain (Momin, Cadiou, Mason, & McNaughton, 2008). HCN2 (Emery et al., 2011;
Schnorr et al., 2014), but not HCN1 (Momin et al., 2008) or HCN3 (Lainez, Tsantoulas, Biel, &
McNaughton, 2019) contributes to mechanical and thermal hyperalgesia; however, the role of
HCN2 varies with the model under study. When Complete Freund’s Adjuvant (CFA) was
injected into the plantar surface of the hindpaw to elicit persistent inflammation, HCN2 knock
out in sensory afferent neurons prevented mechanical but not thermal hyperalgesia on day 3 postCFA (Schnorr et al., 2014). In contrast, ablation of HCN2 in sensory afferents prevented thermal
but not mechanical hyperalgesia from 30min to 3hr after intra-plantar injection of the potent
inflammatory mediator, PGE2 (Emery et al., 2011). Moreover, genetic ablation of HCN2 in
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primary sensory afferents prevented both mechanical and thermal hyperalgesia from 2 to 21 days
after the induction of neuropathic pain by chronic constriction of the sciatic nerve (Emery et al.,
2011). Loss of HCN2 in primary sensory afferents also significantly reduced the pain behavior
that is typically observed 1hr after intra-plantar injection of 4% formalin (licking, biting and paw
lifting), and that is thought to be due to release of inflammatory mediators (Emery et al., 2011).
These data suggest that there are likely to be numerous mechanisms that regulate HCN2 channels
over multiple time courses, and that each mechanism may be differentially activated in a celltype-specific manner and according to the catalyst(s) that triggers the pain state.
Current analgesic strategies to reduce Ih focus mainly on the development of isoform
selective HCN channel blockers, e.g. small molecules that preferentially block channels
containing HCN1 and/or HCN2 subunits (Dini et al., 2018; Resta et al., 2018). More generally,
knowledge about the molecular mechanisms that alter ionic currents during pathological pain is
being exploited to develop novel anti-nociceptive drugs tailored to a specific modulatory
mechanisms (Francois-Moutal, Scott, et al., 2018; Moutal, Yang, et al., 2017). Several
intracellular signalling pathways are known to drive nociceptor sensitization (Basbaum et al.,
2009; Cheng & Ji, 2008; Djouhri, Dawbarn, Robertson, Newton, & Lawson, 2001; Hucho &
Levine, 2007), but details on their modulation of HCN2 channels are limited.
A variety of molecular mechanisms may underpin the increase in nociceptor Ih during
chronic pain states. Altered nociceptor HCN2 channel expression has been observed in multiple
subcellular compartments during pathological pain, including the soma, peripheral terminals,
central terminals, and along axons in nerves (Acosta et al., 2012; Papp, Hollo, & Antal, 2010;
Schnorr et al., 2014; Smith, Al Otaibi, Sathish, & Djouhri, 2015; Weng et al., 2012). In some
models of neuropathic pain, somatic nociceptor HCN2 protein expression appeared to decrease
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despite an increased Ih (Chaplan et al., 2003; Jiang et al., 2008; Liu, Feng, & Zhang, 2015). In
these cases, the decrease in expression may represent compensation for prolonged nociceptor
hyperexcitability, or redistribution of the channels from soma to axon. In other models of
inflammatory pain, both Ih and HCN2 protein expression increased (Acosta et al., 2012; Cho,
Staikopoulos, Furness, & Jennings, 2009; Forster, Jansen, Rubaharan, Murphy, & Baro, 2020b;
Papp et al., 2010; Richards & Dilley, 2015; Schnorr et al., 2014; Smith et al., 2015; Weng et al.,
2012). In most instances, it was not clear if altered expression represented an adjustment to
transcription, translation, and/or post-translational modifications that modify channel turnover.
The rat model of CFA-induced chronic inflammatory pain highlights the idea that multiple
mechanisms may be regulating HCN2 channels over different time courses. Unilateral, intraplantar CFA injection elicits persistent inflammation and chronic pain in the ipsilateral hindlimb
that is resolved by 14-21 days (W. M. Li et al., 2005; Millan et al., 1988). HCN2 expression is
enhanced in multiple subcellular compartments leading to mechanical hyperalgesia (Acosta et
al., 2012; Papp et al., 2010; Schnorr et al., 2014; Weng et al., 2012). A detailed
immunohistochemical examination of somatic HCN2 protein expression in lumbar 5 (L5) DRG
neurons that innervate the hindlimb showed that HCN2 immunoreactivity significantly increased
on day 1 post-CFA in small and medium neurons relative to control animals that did not receive
CFA injections (Forster et al., 2020b). HCN2 staining intensity then returned to baseline by day
3, but the number of neurons expressing HCN2 significantly increased (Forster et al., 2020b). By
days 5-7 post-CFA, HCN2 staining intensity was once again significantly increased, and the
number of neurons expressing HCN2 remained elevated relative to controls (Weng et al., 2012).
In these studies, DRG neurons were only identified by soma size, and it is not known if all
changes occurred in one cell type, or if HCN2 expression was altered in different cell types at
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distinct time points. It is noteworthy that changes in somatic HCN2 protein expression on days 1
and 3 post-CFA were bilateral, while chronic pain only occurs in the ipsilateral hindlimb (Millan
et al., 1988; Schnorr et al., 2014). This suggest that an increase in HCN2 protein expression may
be necessary, but that the supplemental channels are not sufficient to produce pathological pain.
One possibility is that a second ipsilateral mechanism acts on the supplemental HCN2 channels
to alter their function and/or subcellular location.
It is well documented that HCN2 channel function is regulated by cAMP. Binding of
cAMP to the channel’s CNBD significantly shifts voltage dependence to more positive
potentials, which will increase Ih under physiological conditions. DRG cAMP levels are elevated
in models of chronic pain, and enhanced cAMP concentrations lower nociceptive thresholds and
lead to hyperalgesia (Taiwo & Levine, 1991; Tsantoulas et al., 2017; Tsantoulas et al., 2016).
Agonists of Gi/o-coupled receptors that reduce cAMP produce analgesia (Resta et al., 2016). In
some models of neuropathic pain, genetic ablation of PKA had no effect on hyperalgesia,
suggesting that direct binding of cAMP to the channel CNBD could increase Ih (Herrmann et al.,
2017; Malmberg et al., 1997). In contrast, PKA is necessary for CFA-induced inflammatory pain
(Herrmann et al., 2017). Knocking out either HCN2 or PKA prevented CFA-induced
pathological pain, but deletion of the CNBD domain from the HCN2 channel had no effect on
pain thresholds (Herrmann et al., 2017). Furthermore, on days 5-7 post-CFA, C-fiber but not A𝛿
nociceptors showed enhanced excitability due to a significant increase in Ih activation kinetics
and amplitude, but there was no change in Ih voltage dependence of activation (Djouhri et al.,
2015; Weng et al., 2012). PKA is known to phosphorylate HCN2 (Herrmann et al., 2017). Thus,
the existing data suggest that CFA-induced persistent inflammation triggers cAMP activation of
PKA, and perhaps, PKA phosphorylation of HCN2, which somehow leads to an increase in Ih.
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HCN2 𝛼-subunits interact with several auxiliary subunits that modify channel function,
stability and surface expression (Brandt et al., 2009; Kimura, Kitano, Nakajima, & Nakanishi,
2004; Michels et al., 2008; Nawathe et al., 2013; Qu et al., 2004; Santoro, Wainger, &
Siegelbaum, 2004). Protein-protein interactions can be regulated by post-translational
SUMOylation (Flotho & Melchior, 2013). Small Ubiquitin-like MOdifier (SUMO) peptides are
post-translationally conjugated to lysine residues on target proteins, e.g. HCN2. The SUMO
moiety can then promote or prevent interactions between the target and its interacting partners.
There are 4 SUMO isoforms (SUMO1-4): SUMO2 & SUMO3 (SUMO2/3) are ~97% identical;
SUMO1 shares 47% identity with SUMO2/3; the physiological relevance of SUMO 4 is unclear.
The majority of SUMOylation (~65%) occurs within identifiable consensus sequences (Hendriks
et al., 2015), and HCN2 has several putative SUMOylation sites (Parker et al., 2017). HCN2
SUMOylation at K669 increased channel surface expression and Ih maximal conductance in a
heterologous expression system (Parker et al., 2017). Inflammation causes a global increase in
the SUMOylation of DRG proteins, and experimentally enhanced SUMOylation in sensory
neurons produced pathological pain (Y. Wang et al., 2018a). In a rat model of CFA-induced
inflammatory pain, HCN2 SUMOylation was increased in small DRG neurons on days 1 and 3
post-CFA (later times not examined) (Forster et al., 2020b). A target protein’s phosphorylation
status often determines its ability to be SUMOylated (Dustrude et al., 2016; Flotho & Melchior,
2013). Activation of the adenylyl cyclase-cAMP-PKA axis in an identified pattern generating
neuron permitted the post-translational SUMOylation that led to an enhanced Ih (Parker et al.,
2019). Thus, inflammatory mediators acting through PKA could alter the phosphorylation status
of HCN2 channels to permit their SUMOylation, which could enhance surface expression.
SUMOylation of HCN2 channels is dynamically regulated as inflammation progresses.
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SUMO2/3 conjugation to HCN2 increased at day 1 post-CFA, and SUMO1 conjugation to
HCN2 increased at day 3 post-CFA (Forster et al., 2020b). These data imply that inflammatory
mediators regulate HCN2 interaction with components of the SUMOylation machinery that show
target and SUMO-isoform specificity (Flotho & Melchior, 2013).
The rat hindpaw is innervated by sensory neurons in L4-L6 DRG. We previously
reported the effects of CFA injection on HCN2 expression and SUMOylation in L5 DRG. Here,
we complete the study and document changes in HCN2 expression and SUMOylation in L4 and
L6.

3.3

Materials and methods

3.3.1 Animal Ethics
Ethics approval was obtained from the Institutional Animal Care and Use Committee at Georgia
State University and all experiments were performed in compliance with the Ethical Issues of the
International Association for the Study of Pain and the National Institutes of Health (NIH). 60day old, male Sprague-Dawley rats were pair housed in a 12-hr light/dark cycle (lights on at
0700 hr) with ad libitum access to food and water.
3.3.2 CFA model and tissue preparation
A detailed description is found in Forster et al (Forster et al., 2020b). Briefly, 60-day old, male
Sprague Dawley rats were injected with 200 µl of CFA into the mid-plantar surface of the right
hindpaw. Control animals were handled, but not injected. 1 or 3 days later, animals were
anesthetized, injected with heparin and perfused. Animals were fixed with 4%
paraformaldehyde. Bilateral L4 and L6 DRG were extracted and placed into an 18% sucrose

Regulation of HCN2 by SUMOylation

59

solution at 4°C overnight. The following day, the epineurium was removed and DRG were
embedded in 0.3% gelatin and sliced into 20 µm cryosections.
3.3.3 Antibodies and Reagents
The antibodies, dilution factors and applicable experiments are found in Forster et al (Forster et
al., 2020b).
3.3.4 Immunohistochemistry and analysis
IHC was performed as previously described (Forster et al., 2020b). For each DRG, three 5x
magnification images were taken. Blind analysis was performed on Photoshop. Images were
thresholded to remove the intensity of the sheath. All cells above threshold with a definitive
nucleus and visible cell perimeter were HCN2+ cells. Cells below threshold but meeting these
quantification requirements were considered HCN2-. HCN2+ cells were sorted into classes by
diameter: small  30 µm, medium 30- 40 µm and large  40 µm. All gray mean values within a
size class were averaged and is represented as the mean pixel intensity of that size class. The
number of HCN2+ cells within a size class were divided by the sum of all HCN2+ and HCN2cells and is represented as the frequency of that class. IHC experiments were repeated on 6 or 7
experimental animals and 4 or 5 control animals for L4 and L6 DRG at day 1 and day 3.
3.3.5 Proximity ligation assays and analysis
PLAs were performed using Duolink® In Situ Red Kit and manufacturer’s guidelines as
previously described (Forster et al., 2020b). Images were captured with a Zeiss 700 confocal
microscope using a 40x oil immersion objective. Three cryosections were examined per DRG
with a minimum of 3 z-stacks per cryosection. Blind analyses were performed using the FIJI
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version of ImageJ. Cells with a visible nucleus, clear cell boundaries and no overlap with
neighboring cells or fibers were selected for quantification. Maximum intensity projections of 5
z-slices from the middle of the cells were created. Cells were outlined and thresholded using the
triangle method. Watershed analysis divided coalesced signals. For each cell, the average
number of puncta was divided by the cell area to obtain puncta/µm2. The mean pixel intensity
(MPI) within 1 cell was processed by a program created by Alex Perez. PLA experiments were
repeated on 6 experimental and 3 control DRG for L4 and L6 DRG at day 1 and day 3.
3.3.6 Statistics
All statistical analyses were preformed using GraphPad Prism. All data were tested for
normality. The data for left and right DRG from each control animal were combined, because
paired t-tests indicated left and right DRG showed no significant differences. IHC data were
analyzed with a one-way ANOVA followed by Tukey’s post hoc or Kruskal-Wallis followed by
Dunn’s post-hoc. Multiple comparison tests showed no significant differences in HCN2
SUMOylation between control and experimental DRG, therefore control data are not shown.
Normal PLA data were measured using paired t-tests between ipsilateral and contralateral DRG.
Non-parametric PLA data were analyzed with Wilcoxon-matched pairs. All values are presented
as mean ± SEM. p < 0.05 was considered statistically significant.
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Results

3.4.1 HCN2 expression and SUMOylation in L4 DRG neurons on days 1 and day 3 postCFA
CFA was injected into the right hindpaw of experimental animals to elicit persistent
inflammation, while control animals were handled, but not injected. Bilateral L4 and L6 DRG
were dissected at day 1 or day 3 post-CFA and cryosectioned for immunohistochemistry (IHC)
or proximity ligation assays (PLA), as previously described (Forster et al., 2020b). The IHC
experiments were used to measure the level of HCN2 expression in a given cell (mean pixel
intensity) and the percent of HCN2 expressing cells (frequency) in small (≤ 30 µm), medium
(30- 40 µm) and large (> 40 µm) neurons. Values for left and right control DRG were not
significantly different from each other; therefore, left and right values were combined and the
datum for one control animal represents the average for left and right DRG. PLA experiments
measured the number of SUMOylated HCN2 channels (puncta/µm2) or the extent to which
HCN2 channels were SUMOylated (puncta intensity) in ipsilateral relative to contralateral DRG.
Figure 1 shows representative cryostat sections and the results for L4 DRG 1 day postCFA. A significant ~53% increase in HCN2 IR was observed in both ipsilateral and contralateral
small cells relative to control (contralateral: 22.5 ± 1.5; ipsilateral: 23.4 ± 1.5; control: 15.0 ±
1.8) (Figure 1b). There were no significant differences in medium or large cell IR (Medium
contralateral: 24.0 ± 2.0; ipsilateral: 25.8 ± 2.3; control: 18.4 ± 3.0) (Large contralateral: 27.2 ±
1.9; ipsilateral: 28.2 ± 2.8; control: 20.4 ± 3.6). In contrast, Figure 1c shows that CFA-injection
produced a bi-lateral increase in the number of medium and large, but not small cells expressing
HCN2 (Small contralateral: 37.3 ± 5.0; ipsilateral: 38.6 ± 5.6; control: 25.0 ± 5.5) (Medium
contralateral: 19.1 ± 1.3; ipsilateral: 19.9 ± 2.1; control: 12.7 ± 1.0) (Large contralateral: 20.8 ±
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1.7; ipsilateral: 20.6 ± 1.5; control: 13.1 ± 2.5). These experiments did not reveal any CFAinduced change in post-translational SUMOylation of HCN2 channels. There were no significant
differences in the number or intensity of puncta between ipsilateral and contralateral L4 DRG 1
day post-CFA for any size class (Figure 1e,f).
These experiments did not reveal any CFA-induced change in HCN2 expression or posttranslational SUMOylation in L4 DRG on day 3 post-CFA. There were no significant differences
in HCN2 mean pixel intensity (Figure 2a) or frequency (Figure 2b) for any size class. The
number (Figure 2c) and intensity (Figure 2d) of puncta were similar in ipsilateral and
contralateral L4 DRG.
3.4.2 HCN2 expression and SUMOylation in L6 DRG neurons on days 1 and day 3 postCFA
In the L6 DRG 1 day post-CFA, HCN2 expression bilaterally increased in experimental small
cells relative to controls (Figure 3a). The mean pixel intensity was ~65% greater for
experimental compared to control animals (contralateral: 25.5 ± 1.8; ipsilateral: 27.6 ± 2.2;
control: 16.1 ± 1.1). Although mean pixel intensity increased in experimental vs. control for both
medium and large cells, it was not statistically significant. There were no significant changes in
HCN2 frequency for any size class (Small contralateral: 44.3 ± 4.2; ipsilateral: 54.1 ± 4.7;
control: 42.1 ± 4.2) (Medium contralateral: 17.3 ± 1.9; ipsilateral: 17.6 ± 1.8; control: 16.0 ± 2.1)
(Large contralateral: 13.3 ± 1.9; ipsilateral: 11.7 ± 1.3; control: 14.0 ± 2.8) (Figure 3b). There
was a small but significant increase in the number of SUMOylated HCN2 channels in medium
and large neurons (Figure 3c). The differences were isoform specific with SUMO 1 vs. SUMO
2/3 modification increasing in medium vs. large cells, respectively. There were no significant
changes in puncta intensity (Figure 3d).
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In the L6 DRG on day 3 post-CFA, there were no significant differences in HCN2
immunoreactivity (Figure 4a) or frequency (Figure 4b) for any L6 DRG neuronal size class.
There were no significant changes in the number of SUMOylated HCN2 channels (Figure 4c). In
contrast, HCN2 SUMO2/3 puncta intensity was significantly increased in ipsilateral small and
medium cells, but not in large cells (Figure 4d).

3.5

Discussion

In this work, we investigated HCN2 expression and SUMOylation in L4 and L6 DRG at days 1
and 3 post-CFA injection. Using IHC, we found a bilateral increase in HCN2 mean pixel
intensity in small neurons from L4 and L6 DRG at day 1, but expression levels returned to
baseline by day 3. The number of medium and large neurons expressing HCN2 also transiently
increased in L4 DRG on day 1 post-CFA. Using PLA, we found that HCN2 SUMOylation
increased in L6 DRG at days 1 and 3. The number of SUMOylated HCN2 channels increased in
medium and large cells at day 1, whereas the extent of HCN2 SUMOylation was enhanced in
small and medium cells at day 3.
The patterns of change in HCN2 expression and SUMOylation are distinct for each of the
lumbar DRG (Tables 1&2). This is not surprising given that for each DRG a different fraction of
neurons project to the hindpaw. Whereas most neurons in the L5 DRG project to the hindpaw
(Rigaud et al., 2008; Swett, Torigoe, Elie, Bourassa, & Miller, 1991), afferents in the L4 DRG
project to the hindlimb, knee and hip joint (Nakajima et al., 2008; Rigaud et al., 2008; Salo &
Theriault, 1997), and the neurons in L6 DRG mainly innervate visceral organs (Herrity, Rau,
Petruska, Stirling, & Hubscher, 2014; Rigaud et al., 2008; Swett et al., 1991). Changes occurred
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in all size classes of neurons, which is consistent with the fact that both C-fiber and A𝛽 fibers
respond to CFA-induced inflammation (Belkouch et al., 2014).
Despite the fact that neurons in L4-L6 DRG differentially innervate the hindpaw, Table 1
shows that most changes in HCN2 expression occurred to the same extent in ipsi- and contralateral DRG for all 3 lumbar levels. This generalized change suggests that altered expression of
HCN2 is likely to be a systemic response to CFA injection (Koltzenburg, Wall, & McMahon,
1999), which is not sufficient for the development of inflammatory pain at these time points. In
contrast, Table 2 shows increased SUMOylation is observed exclusively in the ipsilateral side
and may make a more direct contribution to the pain phenotype. In that respect, and given that
SUMOylation of HCN2 is known to enhance surface expression of the channel (Parker et al.,
2017), it may be that in DRGs where SUMOylation is increased, surface expression of HCN2 is
also increased without necessarily altering total expression. Alternatively, SUMOylation of
HCN2 may have a direct effect on the gating of the channel. There are several examples of
SUMOylation altering ion channel biophysical properties (Benson et al., 2007; Dai, Kolic,
Marchi, Sipione, & Macdonald, 2009; Plant et al., 2010; Plant et al., 2016; Steffensen et al.,
2018; Y. Wang et al., 2018a; Meghyn A. Welch et al., 2019; Xiong et al., 2017). In our previous
study, enhanced HCN2 SUMOylation in HEK cells did not alter Ih voltage dependence or
kinetics (Parker et al., 2017). However, this result must be interpreted in the context of
significant experimental caveats. First, since SUMO regulates protein-protein interactions, the
effect of HCN2 SUMOylation will depend upon the available complement of interacting
proteins, and the HCN2 interactome varies between cell types. Second, in our HEK cell
experiments the level of HCN2 SUMOylation was altered in an uncontrolled fashion simply by
increasing the cytosolic concentration of SUMO and the SUMO conjugating enzyme, ubc9.
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HCN2 has multiple putative SUMOylation sites, but this manipulation increased SUMOylation
at just a single site, so all potential effects of enhanced SUMOylation may not have been
observed. Third, modulators play a permissive role in SUMOylation (Parker et al., 2019), and the
phosphorylation state of a protein determines which sites can be SUMOylated (Dustrude et al.,
2016; Flotho & Melchior, 2013). Thus, inflammatory mediators that alter phosphorylation states
will likely produce a distinct pattern of HCN2 SUMOylation and associated effects that would
not be replicated in the HEK cell experiments.
Emerging data suggest that altered SUMOylation may drive changes in several ion
channels during nociceptor sensitization. The SUMOylation status of hundreds of proteins in a
single cell is altered in response to a cellular stressor (Hendriks et al., 2015; Seifert, Schofield,
Barton, & Hay, 2015). Chronic inflammation resulted in hyper-SUMOylation of the heat sensing
TRPV1 channel, which lowered the temperature threshold of activation and led to thermal
hyperalgesia (Y. Wang et al., 2018a). CRMP2, a subunit of the NaV1.7 channel, is hyperSUMOylated in a rat model of chronic neuropathic pain, which enhances the sodium current;
and, blocking CRMP2 hyper-SUMOylation in DRG neurons prevented mechanical and thermal
hyperalgesia (Dustrude et al., 2016; Dustrude, Wilson, Ju, Xiao, & Khanna, 2013; FrancoisMoutal, Dustrude, et al., 2018; Moutal, Dustrude, et al., 2017). A ~2-fold change in CRMP2
SUMOylation was observed in sciatic nerve, dorsal horn and glabrous skin during neuropathic
pain (Moutal, Dustrude, et al., 2017) suggesting that larger changes in HCN2 SUMOylation may
be observed in subcellular compartments such as axons and terminals relative to somata.
Additional ion channels are known to be SUMOylated including Kv4 (Meghyn A. Welch et al.,
2019), Kv11 (Steffensen et al., 2018), Kv7 (Qi et al., 2014; Xiong et al., 2017), Kv2 (Plant et al.,
2011), K2P1 (Plant et al., 2010; Rajan et al., 2005), Kv1.5 (Benson et al., 2007), NaV1.2 (Plant
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et al., 2016) and NaV1.5 (Plant et al., 2020). Their SUMOylation patterns have not yet been
ascertained during chronic pain.
In sum, CFA-induced inflammation results in HCN2-dependent mechanical hyperalgesia.
Inflammation-induced alterations in lumbar DRG sensory neurons include altered HCN2
expression and post-translational SUMOylation. Multiple mechanisms regulate HCN2 during the
time course of CFA-induced inflammation. Identification of these mechanisms and the cell type
in which they occur are worth further study.
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Figure 3-1 HCN2 protein expression but not SUMOylation is altered in the L4 DRG 1
day post-CFA.
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A) Representative images of HCN2 IR. Scale bars are 100 µm. B) HCN2 mean pixel intensity is
elevated in small diameter DRG neurons. Average mean pixel intensity ± SEM is shown for
three size classes of DRG neurons (small: ≤ 30 µm; medium: 30- 40 µm; large: > 40 µm). Each
dot represents the mean for one animal. Note that data for left and right DRG from each control
were combined, because paired t-tests indicated left and right DRG showed no significant
differences. The total number of cells examined for all animals within the treatment group is
indicated in the bar. Asterisks indicate significance, *p < 0.05. Small cells: Kruskal-Wallis with
Dunn’s post-hoc test (2,16)=7.750; p=0.014; medium cells: one-way ANOVA F(2,16)=2.378;
p=0.125; large cells: one-way ANOVA F(2,15)=2.158; p=0.150. C) The percent of medium and
large diameter neurons expressing HCN2 increases 1 day post-CFA. Plot of percent HCN2
positive cells for each size class (frequency = # HCN2 positive cells for that size class ÷ total cell
number for all classes). Bars indicate mean ± SEM. Asterisks indicate significance, *p < 0.05.
Small cells: Kruskal-Wallis (2,16)= 3.441; p=0.184; medium cells: one-way ANOVA with
Tukey’s post hoc test F(2,16)= 4.901; p=0.022; large cells: one-way ANOVA with Tukey’s post
hoc test F(2,15)= 5.188; p=0.019. D) Representative confocal projections (5 µm) from PLA
experiments. Scale bars are 25 µm. E) The number of SUMOylated HCN2 channels is unaltered
1 day post-CFA. The number of puncta/µm2 for HCN2 SUMO1 (light bars) and SUMO2/3 (dark
bars) conjugation is shown for three size classes of DRG neurons (small: ≤ 30 µm; medium: 3040 µm; large: > 40 µm). SUMO1; small: 0.458 ± 0.054 vs 0.456 ± 0.032, p=0.979, paired t-test;
medium: 0.424 ± 0.038 vs 0.429 ± 0.032, p>0.999, Wilcoxon-matched pairs; large: 0.505 ±
0.065 vs 0.528 ± 0.039, p=0.740, paired t-test; SUMO2/3; small: 0.405 ± 0.031 vs 0.469 ± 0.048,
p=0.271, paired t-test; medium: 0.394 ± 0.037 vs 0.467 ± 0.050, p=0.181, paired t-test; large:
0.467 ± 0.032 vs 0.584 ± 0.038, p=0.068, paired t-test. Inset: compares the means for
contralateral and ipsilateral DRG for each animal. F) SUMOylated HCN2 Puncta Intensities are
unaltered 1 day post-CFA. Plot of average puncta intensity ± SEM for each size class. SUMO1;
small: 57.86 ± 9.486 vs 55.55 ± 9.556, p=0.615, paired t-test; medium: 57.24 ± 9.442 vs 54.76 ±
9.484, p=0.643, paired t-test; large: 58.37 ± 9.707 vs 56.34 ± 9.626, p=0.679, paired t-test;
SUMO2/3; small: 62.71 ± 7.576 vs 60.19 ± 10.08, p=0.785, paired t-test; medium: 62.44 ± 7.471
vs 60.60 ± 10.21, p=0.824, paired t-test; large: 63.80 ± 7.816 vs 63.46 ± 10.79, p=0.975, paired ttest.
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Figure 3-2 HCN2 protein expression and HCN2 SUMOylation are unaltered in the L4
DRG 3 days post CFA.
A) HCN2 mean pixel intensities do not change 3 days post-CFA. Average mean pixel intensity ±
SEM is shown for three size classes of DRG neurons (small: ≤ 30 µm; medium: 30- 40 µm;
large: > 40 µm). Each dot represents the mean for one animal. Note that data for left and right
DRG from each control were combined, because paired t-tests indicated left and right DRG
showed no significant differences. The total number of cells examined for all animals within the
treatment group is indicated in the bar. Small cells: one-way ANOVA F(2,12)=0.090; p=0.915;
medium cells: Kruskal-Wallis (2,14)=0.438; p=0.819; large cells: one-way ANOVA
F(2,14)=0.330; p=0.725. B) The percent of HCN2 expressing cells does not change 3 days postCFA. Plot of percent HCN2 positive cells for each size class (frequency = # HCN2 positive cells
for that size class ÷ total cells number for all classes). Bars are mean ± SEM. Small cells: one-
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way ANOVA F(2,12)=0.581; p=0.574; medium cells: Kruskal-Wallis (2,14)=1.358; p=0.531;
large cells: one-way ANOVA F(2,14)=0.176; p=0.840. C) The number of SUMOylated HCN2
channels is unaltered in L4 DRG neurons. The number of puncta/µm2 for HCN2 SUMO1 (light
bars) and SUMO2/3 (dark bars) conjugation is shown for three size classes of DRG neurons
(small: ≤ 30 µm; medium: 30- 40 µm; large: > 40 µm). SUMO1; small: 0.473 ± 0.068 vs 0.412 ±
0.031, p= 0.307, paired t-test; medium: 0.465 ± 0.076 vs 0.393 ± 0.041, p=0.418, paired t-test;
large: 0.456 ± 0.066 vs 0.466 ± 0.040, p=0.847, paired t-test; SUMO2/3; small: 0.479 ± 0.059 vs
0.438 ± 0.047, p=0.121, paired t-test; medium: 0.431 ± 0.067 vs 0.361 ± 0.043, p=0.236, paired
t-test; large: 0.446 ± 0.069 vs 0.417 ± 0.047, p=0.562, paired t-test. Inset: compares the means
for contralateral and ipsilateral DRG for each animal. D) SUMOylated HCN2 Puncta Intensities
are unaltered in L4 DRG neurons. Plot of average puncta intensity ± SEM for each size class.
SUMO1; small: 56.16 ± 4.766 vs 64.04 ± 8.799, p= 0.382, paired t-test; medium: 54.92 ± 4.379
vs 63.08 ± 9.142, p=0.400, paired t-test; large: 56.32 ± 4.917 vs 65.79 ± 11.18, p=0.423, paired ttest; SUMO2/3; small: 59.62 ± 6.125 vs 61.62 ± 8.081, p=0.836, paired t-test; medium: 59.44 ±
6.444 vs 64.02 ± 8.447, p=0.609, paired t-test; large: 61.18 ± 6.817 vs 64.59 ± 7.984, p=0.691,
paired t-test.
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Figure 3-3 HCN2 protein expression and HCN2 SUMOylation are enhanced in the L6
DRG 1 day post-CFA.
A) HCN2 mean pixel intensity is elevated in small diameter neurons. Average mean pixel
intensity ± SEM is shown for three size classes of DRG neurons (small: ≤ 30 µm; medium: 3040 µm; large: > 40 µm). Each dot represents the mean for one animal. Note that data for left and
right DRG from each control were combined, because paired t-tests indicated left and right DRG
showed no significant differences. The total number of cells examined for all animals within the
treatment group is indicated in the bar. Asterisks indicate significance, *p < 0.05. Small cells:
one-way ANOVA with Tukey’s post-hoc F(2,15)=7.422; p=0.0060; medium cells: one-way
ANOVA F(2,15)=3.542; p=0.055; large cells: one-way ANOVA F(2,15)=1.338; p=0.292. B)
The percent of HCN2 expressing cells is unaltered 1 day post-CFA. Plot of percent HCN2
positive cells for each size class (frequency = # HCN2 positive cells for that size class ÷ total
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cells number for all classes). Bars indicate mean ± SEM. Small cells: one-way ANOVA
F(2,15)=1.980; p=0.173; medium cells: one-way ANOVA F(2,15)=0.147; p=0.865; large cells:
one-way ANOVA F(2,15)=0.365; p=0.700. C) The number of SUMOylated HCN2 channels
increases in medium and large diameter neurons. The number of puncta/µm2 for HCN2 SUMO1
(light bars) and SUMO2/3 (dark bars) conjugation is shown for three size classes of DRG
neurons (small: ≤ 30 µm; medium: 30- 40 µm; large: > 40 µm). Bars indicate the mean ± SEM.
Asterisks indicate significance, *p < 0.05. SUMO1; small: 0.408 ± 0.068 vs 0.429 ± 0.083,
p=0.574, paired t-test; medium: 0.438 ± 0.068 vs 0.365 ± 0.064, p=0.031, Wilcoxon matchedpairs; large: 0.424 ± 0.046 vs 0.426 ± 0.049, p=0.961, paired t-test; SUMO2/3; small: 0.407 ±
0.069 vs 0.418 ± 0.057, p=0.752, paired t-test; medium: 0.419 ± 0.060 vs 0.372 ± 0.042,
p=0.189, paired t-test; large: 0.488 ± 0.059 vs 0.388 ± 0.042, p=0.018, paired-test. Inset:
compares the means for contralateral and ipsilateral DRG for each animal. D) SUMOylated
HCN2 Puncta Intensities are unaltered 1 day post-CFA. Plot of average puncta intensity ± SEM
for each size class. SUMO1; small: 59.42 ± 8.867 vs 51.48 ± 5.557, p=0.137, paired t-test;
medium: 59.92 ± 9.085 vs 52.20 ± 5.315, p=0.189, paired t-test; large: 59.39 ± 8.740 vs 55.49 ±
9.037, p=0.316, paired t-test; SUMO2/3; small: 61.16 ± 8.501 vs 60.61 ± 8.770, p=0.916, paired
t-test; medium: 60.58 ± 8.002 vs 60.13 ± 9.115, p=0.936, paired t-test; large: 54.74 ± 6.259 vs
51.96 ± 4.790, p=0.655, paired t-test.
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Figure 3-4 HCN2 SUMOylation but not protein expression is altered in the L6 DRG 3
days post-CFA.
A) HCN2 mean pixel intensities do not change 3 days post-CFA. Average mean pixel
intensity ± SEM is shown for three size classes of DRG neurons (small: ≤ 30 µm; medium: 3040 µm; large: > 40 µm). Each dot represents the mean for one animal. Note that data for left and
right DRG from each control were combined, because paired t-tests indicated left and right DRG
showed no significant differences. The total number of cells examined for all animals within the
treatment group is indicated in the bar. Small cells: Kruskal-Wallis (2,13)=2.842; p=0.252;
medium cells: Kruskal-Wallis (2,13)=1.309; p=0.543; large cells: Kruskal-Wallis (2,12)=0.061;
p=0.977. B) The percent of HCN2 expressing cells does not change 3 days post-CFA. Plot of
percent HCN2 positive cells for each size class (frequency = # HCN2 positive cells for that size
class ÷ total cells number for all classes). Bars indicate mean ± SEM. Small cells: one-way
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ANOVA F(2,13)=0.206; p=0.817; medium cells: one-way ANOVA (2,13)=0.043; p=0.958;
large cells: one-way ANOVA F(2,12)=0.932; p=0.420. C) The number of HCN2 SUMOylated
channels is unaltered 3 days post-CFA. The number of puncta/µm2 for HCN2 SUMO1 (light
bars) and SUMO2/3 (dark bars) conjugation is shown for three size classes of DRG neurons
(small: ≤ 30 µm; medium: 30- 40 µm; large: > 40 µm). SUMO1; small: 0.473 ± 0.077 vs 0.418 ±
0.057, p= 0.211, paired t-test; medium: 0.498 ± 0.118 vs 0.413± 0.06, p=0.219, paired t-test;
large: 0.466 ± 0.127 vs 0.427 ± 0.071, p=0.593, paired t-test; SUMO2/3; small: 0.423 ± 0.099 vs
0.389 ± 0.046, p=0.678, paired t-test; medium: 0.424 ± 0.104 vs 0.392 ± 0.073, p=0.563,
Wilcoxon matched-pairs, large: 0.475 ± 0.112 vs 0.417 ± 0.059, p=0.563, Wilcoxon matchedpairs. Inset: compares the means for contralateral and ipsilateral DRG for each animal. D)
SUMOylated HCN2 Puncta Intensities are increased in small and medium cells. Plot of average
puncta intensity ± SEM for each size class. SUMO1; small: 71.29 ± 8.984 vs 65.37 ± 6.805, p=
0.219, Wilcoxon matched-pairs; medium: 73.03 ± 8.633 vs 64.59 ± 6.927, p=0.094, Wilcoxon
matched-pairs; large: 72.02 ± 9.835 vs 66.21 ± 6.770, p=0.313, Wilcoxon matched-pairs;
SUMO2/3; small: 75.83 ± 9.743 vs 63.63 ± 7.899, p=0.031, Wilcoxon matched-pairs; medium:
73.25 ± 9.620 vs 64.71 ± 8.353, p=0.046, paired t-test; large cells: 71.93 ± 6.724 vs 65.46 ±
8.374, p=0.148, paired t-test.
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Table 1: Fold Change in Mean HCN2 Expression in L4-L6 DRG

Fold Change in Mean HCN2 Expression in Experimental DRG relative to Control DRG
HCN2 Expression
Small
Medium
Large
Contralateral
DRG

Ipsilateral
DRG

Contralateral
DRG

Ipsilateral
DRG

Contralateral
DRG

Ipsilateral
DRG

1.5 (± 0.10)
1.4 (± 0.10)
1.6 (± 0.11)

1.6 (± 0.10)
1.5 (± 0.12)
1.7 (± 0.14)

1.3 (± 0.11)
1.3 (± 0.08)
1.4 (± 0.12)

1.4 (± 0.12)
1.4 (± 0.14)
1.5 (± 0.12)

1.3 (± 0.09)
1.2 (± 0.10)
1.3 (± 0.13)

1.4 (± 0.14)
1.4 (± 0.19)
1.3 (± 0.11)

1.5 (± 0.20)
1.7 (± 0.21)
1.1 (± 0.10)

1.5 (± 0.22)
1.5 (± 0.25)
1.3 (± 0.11)

1.5 (± 0.11)
1.0 (± 0.08)
1.1 (± 0.12)

1.6 (± 0.17)
1.1 (± 0.15)
1.1 (± 0.11)

1.6 (± 0.13)
0.8 (± 0.12)
1.0 (± 0.14)

1.6 (± 0.11)
0.9 (± 0.25)
0.8 (± 0.10)

1.0 (± 0.08)
1.4 (± 0.20)
1.2 (± 0.14)

1.1 (± 0.12)
1.3 (± 0.16)
1.4 (± 0.18)

1.1 (± 0.07)
1.4 (± 0.22)
1.1 (± 0.12)

1.1 (± 0.13)
1.3 (± 0.20)
1.2 (± 0.16)

1.0 (± 0.10)
1.4 (± 0.25)
1.1 (± 0.15)

1.2 (± 0.16)
1.3 (± 0.23)
1.2 (± 0.20)

0.8 (± 0.10)
3.0 (± 0.70)
0.9 (± 0.14)

0.8 (± 0.13)
2.6 (± 0.30)
1.0 (± 0.09)

1.0 (± 0.12)
1.8 (± 0.17)
1.0 (± 0.05)

1.2 (± 0.15)
1.7 (± 0.15)
1.0 (± 0.10)

0.9 (± 0.14)
0.7 (± 0.21)
1.1 (± 0.25)

1.1 (± 0.20)
1.0 (± 0.18)
0.7 (± 0.15)

Mean Pixel Intensity Day 1

L4
L5
L6
Frequency Day 1

L4
L5
L6
Mean Pixel Intensity Day 3

L4
L5
L6
Frequency Day 3

L4
L5
L6

Bold values = p < 0.05
± SEM are shown in parenthesis
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Table 2. Fold Change in Mean HCN2 SUMOylation in L4-L6 DRG

Fold Change in Mean HCN2 SUMOylation in Ipsilateral DRG relative to Contralateral DRG
HCN2 SUMOylation
Small
Medium

Large

SUMO1

SUMO2/3

SUMO1

SUMO2/3

SUMO1

SUMO2/3

1.0 (± 0.12)
0.8 (± 0.10)
1.0 (± 0.16)

0.9 (± 0.07)
1.3 (± 0.17)
1.0 (± 0.16)

1.0 (± 0.09)
0.7 (± 0.10)
1.2 (± 0.18)

0.8 (± 0.08)
1.1 (± 0.10)
1.1 (± 0.16)

1.0 (± 0.12)
0.7 (± 0.06)
1.0 (± 0.11)

0.8 (± 0.05)
1.2 (± 0.16)
1.3 (± 0.15)

1.0 (± 0.17)
0.9 (± 0.06)
1.2 (± 0.17)

1.0 (± 0.13)
0.9 (± 0.09)
1.0 (± 0.14)

1.0 (± 0.17)
1.1 (± 0.10)
1.1 (± 0.17)

1.0 (± 0.13)
1.0 (± 0.10)
1.0 (± 0.13)

1.0 (± 0.17)
1.0 (± 0.10)
1.1 (± 0.16)

1.0 (± 0.12)
1.0 (± 0.11)
1.1 (± 0.12)

1.1 (± 0.16)
1.3 (± 0.13)
1.1 (± 0.18)

1.1 (± 0.14)
1.1 (± 0.13)
1.1 (± 0.25)

1.2 (± 0.19)
0.8 (± 0.20)
1.2 (± 0.29)

1.2 (± 0.18)
1.0 (± 0.19)
1.1 (± 0.27)

1.0 (± 0.14)
0.9 (± 0.18)
1.1 (± 0.30)

1.1 (± 0.16)
1.0 (± 0.17)
1.1 (± 0.27)

0.9 (± 0.07)
1.0 (± 0.03)
1.1 (± 0.14)

1.0 (± 0.10)
1.0 (± 0.08)
1.2 (± 0.15)

0.9 (± 0.07)
1.0 (± 0.03)
1.1 (± 0.13)

0.9 (± 0.10)
1.0 (± 0.08)
1.1 (± 0.15)

0.9 (± 0.08)
1.1 (± 0.03)
1.1 (± 0.15)

0.9 (± 0.11)
1.1 (± 0.08)
1.1 (± 0.10)

Puncta/µm2 Day 1

L4
L5
L6
Puncta Intensity Day 1

L4
L5
L6
Puncta/µm2 Day 3

L4
L5
L6
Puncta Intensity Day 3

L4
L5
L6

Bold values = p < 0.05
± SEM are shown in parenthesis
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SUMOYLATION REGULATES RECYCLING OF THE HYPERPOLARIZATION
ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL 2
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Introduction
The hyperpolarization activated, cyclic nucleotide gated ion channel 2 (HCN2) mediates

the slowly depolarizing, hyperpolarization-activated current (Ih) which is permeable to Na+/Ca+
ions. Ih is responsible for regulating the membrane potential of excitable cells, it has a reversal
potential near -30mV which is generally higher than that of the threshold for firing an action
potential (Kase & Imoto, 2012). It is active at hyperpolarized potentials, allowing the cell to
repolarize following an action potential. It is present in the heart in the sinus node to act in
pacemaker functioning and plays a role in the brain in synaptic integration (Wahl-Schott & Biel,
2009). Dysregulation of HCN channels contributes to multiple neurological disease states
including epilepsy, chronic pain, and Parkinson’s Disease (DiFrancesco & DiFrancesco, 2015).
Understanding the regulation of HCN ion channels by mechanisms which can act through
multiple time scales to contribute to these diseases is crucial. One such mechanism of regulation
is post-translational modification (Forster et al., 2020a; Herrmann et al., 2017; Jansen et al.,
2021).
The small ubiquitin like modifier (SUMO) is a ~100 amino acid peptide that is posttranslationally added to lysine (K) resides of target proteins. The E1 activating enzyme utilizes
ATP to conjugate SUMO to itself. Then SUMO is conjugated to the E2 conjugating enzyme
UBC9. UBC9 can conjugate SUMO directly to target proteins or can work in conjunction with
an E3 ligase for target specificity. SUMO can be added to target proteins in a SUMO consensus
motif (ψKXD/E where ψ is a hydrophobic residue and X is any amino acid ) (Flotho & Melchior,
2013) or in a non-consensus sequence with the assistance of an E3 ligase (Streich & Lima,
2016). Non-mutually exclusive effects of SUMOylation of proteins include 1) prevention of
other post-translational modifications that occur at the same lysine residue 2) binding to

Regulation of HCN2 by SUMOylation

79

phosphoinositides in the trans-golgi and plasma membrane 3) prevention of protein-protein
interactions through steric hindrance 4) promotion of protein interactions through SUMO
interaction motif (SIM) domains. SUMOylation is involved in multiple disease states such as
chronic pain, epilepsy, and brain ischemia where regulation of ion channels by SUMOylation is
involved. For example in rodent models of pain there is an increase in SUMOylation of TRPV1
(Y. Wang et al., 2018b), the auxiliary subunit CRMP2 for NaV1.7 (Francois-Moutal, Dustrude,
et al., 2018; Moutal, Dustrude, et al., 2017), and HCN2 (Forster et al., 2020a; Jansen et al.,
2021); mouse models of epilepsy show a decrease in SUMOylation of KV7 and an subsequent
reduction in M-current leading to hyperexcitability (Chen et al., 2021); and during ischemic
conditions in the brain the sodium/calcium exchanger is SUMOylated and may provide a
neuroprotective role (Cuomo et al., 2020). Other ion channels not already mentioned, have been
shown to be SUMOylated including but not limited to Kv4.2 (M. A. Welch, L. A. Forster, S. I.
Atlas, & D. J. Baro, 2019; Welch, Jansen, & Baro, 2021), KV2.1 (Dai et al., 2009; Plant et al.,
2011), KV11 (Steffensen et al., 2018), CaV2.2 (Silveirinha et al., 2021) NaV1.5, and TRPM4
(Kruse et al., 2009).
In our previous studies we showed that SUMOylation of HCN2 K669 increased maximal
conductance (Gmax) by increasing surface expression (Parker et al., 2017). However, we did not
examine the mechanism by which SUMOylation acted to increase the surface expression of the
channel. Here we pick up this story and examine the molecular mechanisms in SUMO regulation
of HCN2 trafficking.
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Methods

4.2.1 Antibodies and plasmids
A plasmid containing mCherry2-Cl was a gift from Michael Davidson (Addgene plasmid
#54563). A plasmid containing SUMO-2 (Kamitani et al., 1998) was a gift from Edward Yeh
(Addgene plasmid #17360). A plasmid containing Ubc9 (Yasugi and Howley, 1996) was a gift
from Peter Howley (Addgene plasmid #14438). We obtained the trip8b plasmid from Bina
Santoro (Santoro et al., 2004). (Santoro et al., 2009). Kv4.2g plasmid was provided by Dax
Hoffman and is the same as we previously used (M. A. Welch et al., 2019; Welch et al., 2021).
HA-KCHIP2a plasmid and HA-DPP10c plasmid were previously generated in or lab (Welch et
al., 2021).
4.2.2 Cell Culture
Hek cells were obtained through ATCC and maintained in EMEM media (Corning, cat.
#10009CV) supplemented with 10% fetal bovine serum (FBS; ATCC 30-2020) and 1%
penicillin-streptomycin (Sigma, cat. #P4333) at 37ᵒC / 5% CO2. Hek-HCN2 stable lines were
previously generated as described in Parker et al 2016. 250 µg/ml of geneticin (Gibco) was used
to maintain selection of HCN2. Stable cell lines were not used past passage number 19. Hek cells
were transiently transfected with Kv4.2g
4.2.3 Calcium Phosphate Transfection
Cells were plated at 1.8 x 106 cells per 60mm culture dish. The following day cells were
transiently transfected with calcium phosphate. 10µg of plasmid DNA was used per transfection
in 220µl total volume in TE buffer (10mM Tris-HCL pH 8, 1mM EDTA). When multiple
plasmids were transfected equal amounts of plasmid DNA were co-transfected with the total
amount of DNA remaining the same. 30µl of 2M CaCl2 was added to the DNA, and then 250µl
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of room temperature 2xHBS (275mM NaCL, 10mM KCl, 12mM dextrose, 1.4mM Na2HPO4,
40mM HEPES, pH 7.05-7.1) was added dropwise while flicking the microcentrifuge tube to mix.
Immediately, the DNA mixture was added dropwise to the cells, and cells were returned to 37ᵒC
/ 5 %CO2 for 4 hours followed by a media change. Cells were allowed to grow and express the
plasmid DNA for ~48 hours before use. Transfection efficiency was assessed by fluorescent
microscopy and only plates with >80% transfection efficiency were used in experiments.

4.2.4 Immunoprecipitation
Cells were transfected with mCherry plasmid DNA, or mCherry + SUMO + UBC9
plasmid DNA 48-72 hours prior to lysing. If >80% transfection efficiency was observed, cells
were lysed with IP lysis buffer (pierce magnetic co-ip kit, supplemented with 20mM NEM and
1:100 protease inhibitor cocktail (Sigma cat. # p8340). 500µg of protein was incubated with 1µl
of anti-GFP (Abcam, ab290), overnight at 4ᵒC, and immunoprecipitated following pierce
magnetic co-IP kit protocol, eluting in 50µl of 2.2M glycine elution buffer before neutralizing in
Tris-base pH 10.4.
4.2.5 Electrophysiology
35mm glass coverslips were covered with 100µg/ml of poly-L-lysine and then 7000010000 cells were plated on them for use 1 day prior to recording. Coverslips were transferred to a
recording chamber perfused with extracellular saline ( in mM: 141 NaCl, 4.7 KCl, 1.2 MgCl2,
1.8 CaCl2, 10 glucose, 10 HEPES, pH 7.4, and osmolarity ∼300-310 mOsm/L). Cells were
visualized using a IX70 Olympus microscope, and transiently transfected cells were identified
with fluorescent microscopy for mCherry or GFP expression. Borosilicate glass was pulled, and
firepolished to generate patch pipettes with a resistance of 2-3MΩ when filled with intracellular
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saline (in mM: 140 KCl, 1 MgCl2, 1 CaCl2, 10 EGTA, 2 MgATP, 10 HEPES, pH 7.2, and
osmolarity ∼290-295 mOsm/L). Pipettes were connected to a MultiClamp 700A amplifier (Axon
Instruments). After forming a G Ω seal, negative pressure was used to break through the
membrane, and only cells that maintained >700 MΩ seal following rupture and had less than 15
MΩ access resistance were examined. Whole cell capacitance was measured upon break-in. Fast
and slow capacitance were compensated. Ih was elicited by holding at -50mV, and then a test
pulse ranging from -50mV to -120mV for ____ in -10mV increments. The difference current was
measured. IA was elicited with a series of 1 s pre-pulses to −90 mV each followed by a 250 ms
test-pulse ranging from −50 to +50 mV in 10 mV increments. The leak current from a prepulse
to -30 mV was subtracted offline. Current (I) was converted to conductance (G) using the
equation G = I/Vm − Vr, with Vm being the membrane potential and Vr being the reversal
potential. For Ih the reversal potential was set to 36 and for Ia the reversal potential was the
reversal potential for potassium, -86mV. The maximal conductance (Gmax) was determined by
plotting conductance against voltage and fitting the data with a first-order Boltzmann equation
using Graphpad Prism. In some experiments, clathrin-mediated endocytosis was blocked with
Pitstop2 (Abcam, ab120687). Cells were treated with 20 µM Pitstop2 for 20 min at 37◦C/5%
CO2 before transferring to the recording chamber, in addition to being included in the
extracellular saline at 20mM.
4.2.6 Immunohistochemistry
15mm coverslips were coated with 100µg/ml of Poly-L-Lysine. Cells were plated onto
the coverslips and used the next day for experiments. Cells were washed 2x with PBS. Then
incubated for 20 minutes at 4C in 4% paraformaldehyde. Cells were washed 1x with PBS briefly,
and then washed 3x – 5 minutes each with PBST (PBS + 0.1% Triton-X-100) to permeabilize the
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membrane. Cells were then incubated for 1 hour at room temperature in 10% normal goat serum
in PBST to block. Block buffer was removed and primary antibodies (GFP 1:1000 sc-9996;
Rab11a 1:100) were added in PBST overnight at 4ᵒC. Primary antibodies were removed and
coverslips were washed 3x with PBST for 5 minutes. Fluorescent labelled secondary antibodies
(goat-anti-mouse-Alexa-488, goat-anti-rabbit-alexa-647) in 10% normal goat serum in PBST are
added to coverslips and incubated for 3 hours at room temperature. Secondary antibodies are
removed, the coverslips are washed 3x with PBS for 5 minutes and then mounted using
Vectasheild non-hardening mounting media (Vector Labs, H-1000) and sealed with clear nail
varnish. Coverslips were imaged using a Zeiss LSM-700 confocal microscope using a 63x oil
immersion objective. Images were then analyzed using colocalization plugins available on FIJI.
4.2.7 Western blotting
After electrophoresis on 10% SDS-PAGE proteins were transferred to PVDF membranes
(Immobilon-P, cat. #IPVH00010) using a wet transfer system at 100mA for 1 hour on ice in
prechilled towbin’s buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.1-8.5).
Membranes were dipped in methanol and allowed to dry for 30 minutes before blocking for 1
hour at room temperature in 5% non fat dry milk in TBS (50 mM Tris-HCl pH7.4, 150 mM
NaCl). Membranes were washed once in TTBS (TBS + 0.1% Tween 20) for 10 minutes. The
membrane was then incubated overnight at 4ᵒC in 1% non-fat dry milk with primary antibodies
while shaking. Membranes were washed 3X 5 minutes in TTBS before incubating in 1% non-fat
dry milk with alkaline phosphatase conjugated secondary antibodies for 2 hours at room
temperature while shaking. Membranes were washed 3X 10 minutes in TTBS and alkaline
phosphatase substrate was placed on the membrane for 5 minutes. Membranes were exposed to
x-ray film (Research Products International) and the chemiluminescent signals were visualized
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using a Kodak X-Omat 2000A imager. The optical density (OD) of the protein of interests was
measured using ImageJ software as previously described (Parker et al., 2017). If a membrane
was stripped and reprobed, the stronger signal was to be the second signal probed for (ie adaptin
first, and GFP second). Membranes were washed 2x in mild stripping buffer for 10 minutes (20
mM glycine, 0.1% SDS, 1% Tween 20, 50 mM KCl, 20 mM Magnesium acetate, pH 2.2), 2x
with PBS for 10 minutes, and 2x with TTBS for 5 minutes. Blots were then exposed to alkaline
phosphatate substrate for 5 minutes, and a 10 minute exposure to xray film, to ensure that all
chemiluminescent signal was gone prior to reprobing the blot. When blots were stripped, 0.1 and
0.2 µg BSA was included on the membrane to normalize the OD of the protein of interest of the
pre-and post- stripped blot to account for any loss of protein during the stripping step. During
stability assays, SYPRO RUBY total protein blot stain (Bio-Rad) was used. Whole cell lysates
(10 µg) were resolved with PAGE and transferred to a PVDF membrane, as described above.
Dried PVDF membranes were incubated protein side face-down in 7% acetic acid/10% methanol
for 15 min and then washed 4X with dH2O for 5 minutes. Membranes floated protein side down
in SYPRO Ruby Protein Blot Stain for 15 min and then washed 3X with dH2O for 1 minute.
Stained protein was visualized using an Omega Ultra Lum imaging system using blue light
transillumination and a 600nm filter. The optical density of the total protein signal in the entire
lane was measured using ImageJ.
4.2.8 Statistics
All statistical analyses were performed using Graphpad prism software. Data were
checked for normality and then performed a t-test or one-way ANOVA or appropriate nonparametric alternatives. Image analysis software for colocalization was performed with plug-ins
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available on FIJI (Fiji Is Just ImageJ), and the mander’s or pearson’s coefficient (colocalization
finder and Coloc 2) for each cell was input into Graphpad for statistical analysis between groups.
4.3

Results
We previously showed that SUMOylation at K669 is associated with an increase in Ih,

and a corresponding increase in surface expression (Parker et al., 2017). To examine the
mechanism responsible for this increase, we first asked if HCN2 internalization is regulated by
SUMOylation of the channel. By using a modified cell surface biotinylation assay, surface
proteins are biotinylated and then lysed and added to neutravidin beads to capture the surface
expressed fraction of HCN2 channels. Internalized channels are measured by after biotinylating
the surface fraction, cells are incubated at 18C for 2.5hr. Proteins remaining at the surface are
stripped of biotin by incubating with a strong reducing agent, MESNA, leaving only proteins that
have internalized during this time period to be labelled with biotin. The cells are lysed and added
to neutravidin beads to capture the internalized HCN2 channels. A control plate where the cells
were not allowed to internalize surface protein was stripped with MESNA prior to lysing (Figure
1A). HEK-HCN2 cells showed 22.87% of channels internalized after 2.5hr (Figure 1B).
Transiently transfecting HEK-HCN2 cells with SUMO and UBC9 prevented internalization of
the channel with only 6.38% internalized (Figure 1B). We next asked if SUMOylation at K669 is
preventing internalization. The cell surface biotinylation experiment was repeated, but this time
we used mutant HCN2-K669R cells where K has been mutated to R to prevent SUMOylation, as
we previously showed (Parker et al., 2017). When HCN2-K669R cells were used only 8% of the
channels internalized after 2.5 hours, and no further effect was observed when SUMO and UBC9
was transiently transfected (Figure 1B). These data suggest that SUMOylation of K669 increases
surface expression and Ih by preventing internalization of the channel.
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We next asked if the decrease in internalization with K669 SUMOylation is regulated by
clathrin-mediated endocytosis. We performed whole cell patch clamp on HEK-HCN2 stable line
that were or were not treated with the clathrin mediated endocytosis inhibitor Pitstop2.
Application of Pitstop2 mediated an 80% increase in Ih Gmax compared to the stable line alone.
When SUMO peptide is included in the patch pipette there is a 62% increase compared to stable
line. However, when both pitstop and SUMO are applied, there is a 71% increase (Figure 2). The
lack of an additive effect of SUMO and Pitstop, suggests that Pitstop both mimics and occludes
the effect of SUMO on Ih. Additionally, we show that the addition of SUMO into the patch
pipette increases Ih through K669, as no effect of SUMO is observed on HEK-HCN2-K669R
cells. This is the same as long-term effects of transient transfections of SUMO and UBC9
plasmids (Parker 2017) (Figure 2B). These data suggest that the effect of acute SUMOylation is
indeed acting on K669 rather than on endocytic machinery at the cell surface.
AP2 is the major adaptor protein during clathrin mediated endocytosis. HCN2 contains 5
AP2 consensus motifs YXXɸ, where X represents any amino acid and ɸ represents a
hydrophobic amino acid, in its c-terminus. AP2 is a heterotetramer consisting of alpha, beta, mu
and omega adaptin subunits. One possibility is that SUMOylation of HCN2 prevents the
association of the channel and AP2 subunits, and this prevents internalization of the channel. To
test this, we preformed co-immunoprecipitation experiments to see if SUMOylation regulated the
amount of alpha-adaptin associated with HCN2. We saw no changes in adaptin protein co-IPed
when HCN2 channel is SUMOylated (Student’s t-test, p=0.6750; 0.3432 + 0.0413 vs 0.3696 +
0.425). These data suggest that SUMOylation is not altering clathrin-mediated endocytosis.
Instead, we hypothesize that SUMOylation is acting downstream of internalization, and instead
is acting to increase recycling of the channel to the plasma membrane. To test this hypothesis, we
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used a dominant negative form of Rab11aS25N where this mutation keeps rab11a in its inactive
GDP bound form. When Rab11aS25N was transiently transfected in HEK-HCN2 cells, we saw
no difference in Ih from control. Additionally, when SUMO was added into the patch pipette,
there was no change in Ih, suggesting that SUMO increases Ih through rab11-dependent
recycling (Figure 4A,B). When pitstop was added into the superfusate, Ih increased, suggesting
that Ih can still increase by preventing channel from being internalized without functional rab11a
mediating recycling of the channel back to the membrane. To support these data, we used antirab11a to label endogenous rab11a in HEK293 cells and measured the amount of GFP-HCN2
and Rab11a colocalization with or without co-transfection with SUMO and UBC9. When SUMO
and UBC9 are transiently transfected we see an increase in colocalization by Pearson’s
colocalization coefficient (student’s t-test, 0.1391 v. 0.1829, p=0.0407), as well as an increase in
Mander’s overlap coefficient (student’s t-test, 0.7618 v. 0.8050, p=0.0003) (Figure 4C,D).
Together these data suggest that SUMOylation of HCN2 increases Ih through increased rab11a
mediated slow-recycling.
Next, we asked if SUMOylation is stabilizing HCN2 protein expression. We ran lysates
from HEK-HCN2 cells either transfected or not with SUMO and UBC9, and normalized GFP
signal to SYPRO RUBY total protein stain. We saw an increase in HCN2 protein when SUMO
and UBC9 were co-expressed (t-test, p=0.0027) (Fig 5A,B). To ask if this was due to
SUMOylation of the channel, we repeated this experiment with HCN2-K669R stable line, and
we also observed an increase in HCN2 protein (Figure 5 A,B). We next asked if SUMOylation
was altering ubiquitination status of the protein and degradation of the channel in the
proteasome. Ubiquitin Anti-FK1 recognizes ubiquitin chains but not free ubiquitin (Fujimuro,
Sawada, & Yokosawa, 1994), we observed no change in ubiquitin chain modification of HCN2
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with or without SUMO (figure 5C). Therefore, the increase in SUMOylation of the channel is
not increasing protein by preventing proteasomal degradation of HCN2. These data suggest that
increasing SUMOylation in HEK cells may be acting at the level of the transcriptome. To test
this hypothesis, we preformed qPCR to measure transcript level of our HEK-HCN2 stable line
with and without SUMO and UBC9 over expressed. We observed a non-significant 33% increase
in copy number, (Figure 5D) that is in line with the 30% increase in protein level we observed
(Figure 5 A,B). Together these data suggest that transiently transfecting SUMO and UBC9
increases HCN2 protein level, but that this does not account for the SUMO mediated increase in
Ih Gmax (Parker et al 2017).
HCN2 interacts with a known auxiliary subunit TRIP8b. Association with the 1a-4
isoform of TRIP8b, the most abundantly expressed isoform in the brain, increases Ih Gmax in
HEK cells. In the brain, this is associated with dendritic enrichment of HCN2 channels and
proper surface expression and localization of the channel in the dendrite. Previously Lewis et al
showed that TRIP8b prevented HCN2 from being targeted to the lysosomes, and in the
hippocampus knocking out trip8b showed an increase in HCN2 protein in multivesicular bodies.
The authors hypothesized that TRIP8b could be acting to direct HCN2 trafficking and
localization, and by preventing targeting to the lysosome could instead be redirecting HCN2 to
the recycling endosomes(Lewis et al., 2009). Additionally, Hardel showed that HCN2 is found in
recycling vesicle pools in the heart and the pool of HCN2 in the endocytic recycling
compartment regulated surface expression of HCN2 (Hardel, Harmel, Zolles, Fakler, & Klocker,
2008). Since we showed that post-translational SUMOylation regulates surface expression
through a rab11a dependent recycling mechanism – we asked if TRIP8b might be acting in the
same pathway as SUMOylation to produce these effects. First, we repeated internalization assays
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and saw as expected that TRIP8b prevented internalization of HCN2 and this was to the same
degree as SUMOylation (Figure 6A,B). Next, we transiently transfected TRIP8b in our HEKHCN2 stable line and saw that TRIP8b did indeed increase Ih Gmax as expected, but no additive
effect of SUMO was observed when SUMO was transiently transfected with SUMO and UBC9
plasmids (Figure 6 C,D) and this was also true with SUMO in the patch pipette (data not shown).
These data suggest that Trip8b and SUMO are acting through the same pathway to increase Ih
Gmax. Next, we transiently transfected HEK-HCN2 with Trip8b and Rab11S25N and observed
that Ih no longer increased as it does when Trip8b is transfected alone. These data suggest that
TRIP8b is acting to shuttle HCN2 through the endocytic pathway to Rab11a positive endocytic
recycling compartments and increases Ih through rab11a dependent recycling in the same
manner as SUMOylation of HCN2 (Figure 6C,D).
We previously examined the mechanism behind the increase in Ia Gmax upon
SUMOylation of Kv4 when expressed in the ternary complex with DPP10c and KChIP2a
(Welch 2021). Here Welch et al showed that SUMOylation prevented internalization of the
channel and that it acted in a clathrin-mediated endocytosis independent manner. Here, I ask if
Kv4.2 TC SUMOylation may be acting to increase Ia Gmax through rab11a dependent recycling
in the same fashion as it does for HCN2. When Rab11aS25N is transiently transfected with
Kv4.2g, KChIP2a and DPP10 and SUMO is or is not included in the patch pipette, we no longer
see an increase in Ia Gmax through SUMOylation (Figure 7A,B). Suggesting that SUMOylation
of the ternary complex is mediating the increase in Ia Gmax through recycling of the channel
back to the surface. Additionally, when pitstop2 was added Ia Gmax increased. This is important
since recycling is downstream of inhibiting endocytosis (Figure 7A,B).
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Discussion
We found that HCN2 SUMOylation at K669 prevented internalization of the channel and

did so in a clathrin-mediated endocytosis independent manner. SUMOylation of the channel
increased the amount of total HCN2 protein, but this was not due to SUMOylation at K669, and
was associated with a non-significant increase in transcript level. Additionally, SUMOylation
increased colocalization of HCN2 with Rab11a, and using a dominant negative form of
Rab11aS25N the effect of SUMOylation of HCN2 was blocked. Together this showed that
SUMOylation of K669 in HCN2 increases surface expression through an increase in recycling of
the channel to the membrane. Additionally, we show that HCN2 association with TRIP8b also
increases surface expression through the rab11a-dependent slow recycling pathway. Finally, we
show that the Kv4.2 ternary complex also acts to increase IA through this same pathway,
suggesting that c-terminal SUMOylation of ion channels may be a common mechanism to
regulate surface expression.
4.4.1 C-terminal SUMOylation of Ion Channels as a Common Mechanism to Regulate
Surface Expression
Both HCN2 and Kv4.2 are SUMOylated in their c-terminus which in turn regulates their surface
expression, Gmax and internalization (Parker et al., 2017; M. A. Welch et al., 2019; Welch et al.,
2021). This may be a common mechanism that is utilized to regulate their surface expression,
perhaps with c-terminal SUMOylation acting as a signal which is recognized by transport
proteins in endocytic compartments to route them to the endocytic recycling compartment and
will require rab11a to recycle the channels back to the plasma membrane as it did for both HCN2
and Kv4.2 ternary complex in HEK293 cells (Figure 4, 7). In fact, other membrane proteins have
c-terminal SUMOylation such as Connexin 43 (Cx43). Cx43 is SUMOylated in its c-terminal tail
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during endocytic transport (Kjenseth et al., 2012). Nephrin also shows c-terminal SUMOylation
and shows increased surface expression compared with cells that were treated with the E1
inhibitor ginkgolic acid. The authors suggest that SUMOylation may be acting to regulate
surface expression of the channel through regulation of recycling of the channel (Tossidou,
Himmelseher, Teng, Haller, & Schiffer, 2014).
4.4.2 Balance of SUMOylation and Ubiquitination to Regulate Surface Expression
Isoform 1a-4 of Trip8b increases surface expression and Ih when transiently expressed with
HCN2 (Lewis et al., 2009) and here we show that Trip8b increases Ih, and when dominant
negative Rab11 is co-transfected with TRIP8b this increase is prevented – suggesting that
theTRIP8b mediated increase in Ih requires the channel to exit the endocytic recycling
compartment. Lewis et al showed that TRIP8b co-expression prevented HCN channel from
trafficking to the lysosome and hypothesized that instead it must be recycled instead (Lewis et
al., 2009) and our data support this original hypothesis. SUMOylation could be acting as a
mediator for cross-talk between the SUMOylation system and the ubiquitination pathways –
possibilities include 1) SUMOylation is preventing ubiquitination of a through SUMOylation of
a K residue that is also a ubiquitination site (Ulman et al., 2021) 2) SUMO moiety causing steric
hindrance preventing the association of ubiquitination machinery 3) SUMOylation increasing the
association of deubiquitinases (DUBs) 4) SUMOylation decreasing the association of ubiquitin
ligases and ubiquitin interacting proteins (Rott et al., 2017). For these scenarios this suggests that
SUMOylation would act to recruit deubiquitinating enzymes or/prevent the addition of a
ubiquitin moiety to the target protein and prevent the protein from being shuttled through the
ESCRT system to be degraded by the lysosome. As such, the protein is left to be able to be
recycled – however this assumes that recycling is a passive/default process – and instead it is
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possible that SUMOylation could be acting to increase sorting to the endocytic recycling
compartment. Our data suggest that SUMOylation of HCN2 increases the association of the
channel with Rab11a (Figure 4) and that functional rab11 is required to mediate the SUMO
effect on Ih (Figure 4). Often, recycling has been viewed as a default and passive process, where
if transmembrane proteins were not actively sorted for degradation, they passively moved on for
recycling (MacDonald, Savage, & Zech, 2020). Instead, there is a highly complex system of
sorting proteins for both degradation by the lysosome and recycling pathways – with ubiquitin
signaling for trafficking being more complex than a single mono-ubiquitin triggering
internalization of a protein and poly-ubiquitination being a signal for proteasomal degradation
(Ronai, 2016) and if ubiquitin moieties remain after the protein is internalized to the early
endosome the protein will be sorted by the ESCRT system to multi-vesicular bodies and the
lysosome for degradation (Weeratunga, Paul, & Collins, 2020).
Proteins such as SUMO targeting ubiquitin ligases (STUbLs) interact with SUMO
modified proteins to ubiquitinate the target, which can then modify the function of the protein or
lead to degradation of the protein by the proteasome(Kumar, Gonzalez-Prieto, Xiao, Verlaan-de
Vries, & Vertegaal, 2017). The StUBl RNF4 can catalyze K48 (proteasome) or K63 (recruitment
of ubiquitin binding motif containing proteins) linked UB chains (Keiten-Schmitz et al., 2020).
Additionally, there are SUMO targeting ubiquitin proteases (STUPs) which can recognize
SUMO modified proteins to modify ubiquitin chains on SUMOylated targets by removing
ubiquitin moieties (Salas-Lloret & Gonzalez-Prieto, 2022). In addition to specialized ubiquitin
ligases/proteases which bind to SUMOylated substrates, SUMOylation may be increasing these
interactions through SUMO-interaction Motifs (SIMs) within ubiquitin ligases or deubiquitin
ligases. Identified first in the nucleus during DNA damage and repair If SUMOylation is acting
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in a similar manner here, we could predict that a decrease in association with a ubiquitin ligase
and/or an increase in association with a deubiquitinase would result in an increase in the amount
of channels recycled to the membrane.
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Figure 4-1 HCN2 SUMOylation prevents internalization of the channel
A) Western blots showing GFP signal of total, stripped, and internal HCN2 for wildtype HEKHCN2 and mutant HEK-HCN2-K669R. B) Graph of the optical density of the internalized
HCN2 doublet divided by the optical density of the total surface fraction of HCN2, (ANOVA
with Tukey’s multiple comparisons, F (4, 15) = 4.886, p=0.01; HEK-HCN2, mCherry 22 ± 6.6
% v. mCherry + SUMO + UBC9 6.4 ± 3.5 %; HEK-HCN2-K669R, mCherry 8.1 ± 7.9 % v.
mCherry + SUMO + UBC9 8.0 ± 5.6 %). Circles = wildtype, Triangles = K669R, Data presented
as mean ± SEM, * represents p<0.05.

Regulation of HCN2 by SUMOylation

95

Figure 4-2 The endocytosis inhibitor, Pitstop2, mimics and occludes the effects of
SUMOylation at K669 on HCN2
A) Representative traces of HEK-HCN2. B) Representative traces of HEK-HCN2-K669R. C)
Graph of Gmax. Ih Gmax significantly increases with SUMO in the pipette or Pitstop2 applied,
but there is no further effect of SUMO when added after pitstop (ANOVA with Tukey’s multiple
comparisons, F(3,31)=4.672, p=0.0083). SUMO has no effect on HEK-HCN2-K669R (t-test,
p=0.9587). Circles = wildtype, Triangles = K669R, data presented as mean ± SEM, * represents
p<0.05.
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Figure 4-3 The effects of HCN2 SUMOylation are not due to clathrin mediated
endocytosis
A) Western blot of α-adaptin (top) from co-ip with GFP (bottom) from HEK-HCN2 cells
transfected with mCherry (left) or mCherry and SUMO and UBC9 (right). B) Graph of optical
density of α-adaptin divided by optical density of GFP. (0.3379 ± 0.03243 v. 0.3696 ± 0.04257,
t-test, p=0.6110). Data presented as mean ± SEM.
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Figure 4-4 SUMOylation increases Ih through Rab11a dependent recycling
A) Representative traces of HEK-HCN2 cells transiently transfected with Rab11aS25N and
either treated or not with SUMO in the pipette or Pitstop bath applied. B) Graph of Ih Gmax.
SUMO in the pipette does not increase Gmax (t-test, p=0.4404; 12.52 ± 1.629 v. 12.18 ± 1.436),
but pitstop can still increase Ih (t-test, p=0.0349; 12.52 ± 1.629 v. 16.03 ± 0.5833) C) Graphs of
pearson’s colocalization coefficient (0.1391 ± 0.09240 v. 0.1829 ± 0.09441, t-test, p=0.0407) and
mander’s overlap coefficient (0.7618 ± 0.05799 v. 0.8050 ± 0.04024, mann-whitney, p=0.0004).
D) confocal microscopy image showing rab11a in magenta, HCN2-GFP in green and DAPI
nuclear stain in blue. Yellow arrows point to perinuclear recycling endosomes. Data presented as
mean ± SEM, * represents p<0.05.
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Figure 4-5 SUMOylation increases HCN2 protein expression through an increase in
transcription of HCN2
A) Western blot of lysates probed for GFP. Doublet between 250 and 150kD represents HCN2
protein. Total SYPRO protein stain of the full lane is shown to the right of the western. The
dashed line separates wildtype and K669R mutant HCN2. B) Graph of the optical density of the
GFP doublet divided by the optical density of the SYPRO stain for the whole lane. Transfecting
with SUMO+UBC9 increases total HCN2 protein in both HEK-HCN2 (0.7750 ± 0.1724 v. 1.097
± 0.0274; t-test, p=0.0027) and HEK-HCN2-k669R (0.7521 ± 0.1322 v. 1.039 ± 0.2839; t-test,
p=0.0487). C) western blot of poly-ubiquitin (anti-FK1) above, and western blot of anti-GFP
below from IP with GFP. Graph to the right shows optical density of anti-FK1 divided by the
optical density of anti-GFP. No significant difference was observed when SUMO+UBC9 was
transfected (0.2001 ± 0.09335 v. 0.1535 ± 0.05912; t-test, p=0.1035). D) Graph of HCN2 copy
number following transfection with and without SUMO + UBC9 (5654 ± 1321 vs. 8455 ± 1822;
t-test, p=0.2414). Data presented as mean ± SEM, * represents p<0.05.
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Figure 4-6 Trip8b acts through the recycling pathway to regulate HCN2
A) Western blots showing GFP signal of total, stripped, and internal HCN2 for wildtype HEKHCN2 and HEK-HCN2 + TRIP8b. B) Graph of the optical density of the internalized HCN2
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doublet divided by the optical density of the total surface fraction of HCN2, (t-test, C)
Representative traces of HEK-HCN2 plus TRIP8b, TRIP8b with SUMO + UBC9, and TRIP8b
and RAB11aS25N. D) Maximal conductance of HEK-HCN2 increases significantly when
TRIP8b is transiently transfected (10.89 ± 1.449 v. 23.40 ± 0.9090), but there is no significant
difference between HCN2 + TRIP8b and HCN2 + TRIP8b + SUMO + UBC9 (21.04 ± 1.504),
ANOVA with Tukey’s multiple comparisons, F (3, 30) = 14.34. HCN2 + TRIP8b + Rab11S25N
is not significantly different from HCN2 + Rab11S25N, but it is significantly reduced from
HCN2 + TRIP8b. Data presented as mean ± SEM, * represents p<0.05.
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Figure 4-7 SUMOylation regulates rab11a dependent recycling of Kv4.2
A) Representative traces of Kv4.2 ternary complex (Kv4.2g + DPP10c + KChIP2a). Scale bars,
500pA by 40ms. B) Graph showing maximal conductance of IA ternary complex. IA
significantly increases after SUMO is added in patch pipette, data adapted from (Welch et al.,
2021). C) Graph showing maximal conductance of IA when Rab11aS25N is transiently
transfected, there is no significant difference between Gmax of the Kv4.2 ternary complex and
Kv4.2 ternary complex with SUMO in the patch pipette, but Gmax still increases with the
endocytosis inhibitor Pitstop2 (ANOVA with Dunnett’s multiple comparisons test, F (2, 19) =
4.238, p=0.0301, 84.73 ± 5.582 v. 82.59 ± 4.699 v. 102.5 ± 4.179). Data presented as mean ±
SEM, * represents p<0.05.
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CONCLUSION

In this dissertation work we show that HCN2 is SUMOylated in the rat DRG by both
SUMO1 and SUMO2/3. HCN2 SUMOylation in the DRG increases after CFA induced
inflammation. The increase in SUMOylation occurs unilaterally, with the changes in
SUMOylation occurring in the ipsilateral DRG when compared to the contralateral DRG.
However, the changes in HCN2 expression occur bilaterally following inflammation. These
results suggest that SUMOylation of the HCN2 channel may be, in part, mediating the changes
in unilateral behavior following inflammation rather than just increases in protein expression.
The mechanism of regulating HCN2 channels following SUMOylation was then explored
further. Here we show that HCN2 SUMOylation increases the maximal conductance of the
channel, and that increases in SUMOylation are associated with an increase in colocalization of
the channel with the endocytic recycling compartment. Using a dominant negative form of
rab11a the effects of SUMOylation were blocked, suggesting that rab11a slow recycling is
mediating the increase in maximal conductance by SUMOylation of HCN2. The effect of
SUMOylation was not dependent on increasing the association of the channel with alphaadaptin, a subunit of AP-2 adaptor protein for clathrin mediated endocytosis. Together these data
suggest that SUMOylation is increasing recycling of the channel, and that clathrin mediated
endocytosis of the channel is not altered by SUMOylation. Additionally, we observed an
increase in expression of the HCN2 protein following SUMOylation. However, this was also
present in the K669R mutant. These data suggest that SUMOylation of K669 is not increasing
stability of the channel. When qPCR was performed, we observed a non-significant but
comparable increase in mRNA when compared to the increase in protein. These data suggest that
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transiently transfecting SUMO and UBC9 increases transcription of the channel which is what is
mediating the increase in protein expression. We next examined the effect of SUMOylation of
the Kv4.2 channel in recycling. SUMOylation of Kv4.2 ternary complex increases Ia Gmax.
When dominant negative rab11a was transiently transfected we no longer observe an increase in
IA gmax following addition of SUMO in the patch pipette. These findings raise some questions.
One, is c-terminal SUMOylation a common mechanism to regulate ion channel recycling? And,
if it is, how is SUMOylation acting? Two, is ion channel SUMOylation increasing the
excitability of DRG neurons during pain?
5.1

C-terminal SUMOylation regulates slow recycling of ion channels
In primary cells, ventricular cardiomyocytes and hippocampal neurons, perinuclear

staining of HCN4 is observed. This staining pattern matched the perinuclear distribution of
HCN1, 2 and 4 observed in opossum kidney cells with the ion channel transiently transfected.
This suggests that the channel may be stored in intracellular compartments. These authors next
investigated recycling of HCN channels through the endocytic recycling compartment. Here they
showed that the recycling endosome compartment regulates the surface expression of HCN2 and
HCN4 in opossum kidney cells. Co-transfection of dominant negative Rab11a reduced the
surface expression of these channels (Hardel et al., 2008). This suggested to us, in combination
with alpha adaptin interaction not changing following SUMOylation of HCN2, that
SUMOylation of the HCN2 channel may be altering recycling of the channel via the slow
recycling pathway through rab11a. While in our study dominant negative rab11a did not reduce
the maximal conductance compared to HCN2 without dominant negative rab11, we were using
different cell types (HEK293 vs OK), and stable transfections vs transient transfections,
dominant negative rab11a did prevent the increase in maximal conductance by addition of
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SUMO in the patch pipette, suggesting that SUMOylation of the channel mediates the increase in
recycling to the cell surface. In addition, Kv4.2 ternary complex uses rab11a to increase
recycling of the channel and increases Ia Gmax when SUMO is added to the patch pipette.
Could SUMOylation of the c-terminus be a common mechanism to regulate surface
expression? In order for a protein to be sorted for recycling, it must first avoid being sorted into
intraluminal vesicles fated for the lysosome during cargo retrieval. Cargo retrieved for recycling
will be sorted into tubular like micro-domains that are then sorted to the endocytic recycling
compartment for slow recycling, or bud off into vesicles that are sent directly back to the plasma
membrane during fast recycling (Cullen & Steinberg, 2018). A marker of the endocytic recycling
compartment is Rab11a, where we used a dominant negative form in order to prevent recycling
of the channel in chapter 4. Deciding the fate of cargo is mediated in part by the endosomal
sorting complexes required for transport (ESCRT) system. In the early endosome, ESCRT-0, and
binds to ubiquitinated proteins and forms clusters of ubiquitinated cargo. ESCRT-I/II also bind to
ubiquitinated proteins and aid to further enrich these regions with ubiquitinated cargo. ESCRTIII does not contain ubiquitin binding domains, but instead is thought to be targeted to these
microdomains of ubiquitinated cargo through the density of ESCRT-II. It brings with it
deubiquitinating enzymes so that the ubiquitinated moieties may be reused (Cullen & Steinberg,
2018).
Ubiquitination serves as both a signal for internalization as well as a sorting signal into
the lysosome. While mono-ubiquitination is generally thought of for internalization and
degradation by the lysosome, endocytic proteins with ubiquitin binding domains can recognize
other forms of ubiquitin modifications such as K63 or K48 linked poly-ubiquitination (Piper,
Dikic, & Lukacs, 2014). Additionally, during internalization there is often multiple mono-
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ubiquitinations or K63-linked polyubiquitination (Boname & Lehner, 2011). During
internalization ubiquitination is a sorting signal recognized by the ESCRT system to route the
channel to either be degraded or recycled. The HCN2 channel has 7 putative ubiquitination sites
in it’s c-terminus (K534, K553, K567, K570, K573, K638 and K639) (X. Li, 2009).
SUMOylation may be increasing or decreasing the association of the ion channel with a
deubiquitinase or ubiquitin ligase, respectively. When mass spectrometry was performed on
Kv4.2 interacting proteins multiple ubiquitin ligases/deubiquitinases were identified (Hu et al.,
2020). It is possible that one of these ligases/deubiquitinases may be influencing Kv4.2s
trafficking following SUMOylation. Indeed, when investigating how SUMO regulates
trafficking of other ion channels, ubiquitination changes were observed. The dopamine
transporter (DAT) is SUMOylated and following SUMOylation there is a decrease in
ubiquitination of DAT, and an increase in plasma membrane levels (Cartier et al., 2019).
SUMOylation of CRMP2 regulates surface expression of the NaV1.7 channel. When CRMP2 is
decorated with SUMO there is a reduction of interaction with Nedd4-2 ubiquitin ligase. Nedd4-2
mono ubiquitinates NaV1.7 and this is associated with internalization of the channel
(Laedermann et al., 2013). Additionally, following CRMP2 SUMOylation there is a reduction in
NaV1.7 association with Eps17, which is required for generating the membrane curvature needed
to internalize the channel (Dustrude et al., 2016). When Smoothened (smo) is SUMOylated there
is an increase in accumulation of the receptor at the plasma membrane. This is mediated in part
by SUMOylation decreasing the amount of ubquitinated smo through recruitment of a SIM
domain containing UBPY deubiquitinase (S. Li et al., 2012; Ma et al., 2016). The deubiquitinase
USP5 interacts with the CaV3.2 channel and decreases channel ubiquitination and leads to an
increase in the Ca2+ current. SUMOylation of USP5 prevents interaction of USP5 and CaV3.2,
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leading to an increase in CaV3.2 ubiquitination and a decrease in the T-Type Ca2+ current
(Garcia-Caballero et al., 2014; Garcia-Caballero et al., 2019). The two pore domain potassium
channel, TWIK, is SUMOylated and SUMOylation may play a role in function expression of the
channel in the plasma membrane. Additionally, it associates with EFA6, which is involved in
clathrin-independent endocytosis. Following internalization these channels are found in the
endocytic recycling compartment (Mathie, Rees, El Hachmane, & Veale, 2010). It is possible
that SUMOylation may be acting in a similar mechanism in this case to enhance recycling and
expression in the plasma membrane as we observed for HCN2 and Kv4.2 in chapter 4. There we
observe an enhancement of SUMOylated HCN2 channels in the endocytic recycling
compartment as seen by the increase in colocalization of HCN2 and Rab11a following
expression of SUMO and UBC9. Performing stable isotope labelling using amino acids in cell
culture (SILAC) we could examine if there are differences in ubiquitin ligases/deubiquitinases
that are associated with the HCN2 channel following over expression of SUMO and UBC9
plasmids when compared to when they are not expressed. This would allow us to predict
ubiquitin associated proteins are differentially interacting with the channel and could then have
follow up experiments to test if they are altering trafficking of the HCN2 channel through whole
cell patch clamp.
5.2

Ion channel SUMOylation increases hyperexcitability of DRG neurons
As described in chapters 2 and 3, HCN2 channels are SUMOylated following

inflammatory pain. Ih is increased following inflammation, and spontaneous activity of c-fibers
are increased following inflammation. The spontaneous activity is blocked following inhibition
of HCN channels. As HCN2 channels protein expression is increased bilaterally following
inflammation, and SUMOylation is changing unilaterally, SUMOylation of the channel may be
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what is mediating the pain behavior following inflammation rather than just a change in protein
expression. Other ion channels are SUMOylated in pain. Preventing their SUMOylation prevents
pain behavior. For example the Nav1.8 channel is associated with the CRMP2 auxiliary subunit.
CRMP2 SUMOylation is increased in the ipsilateral dorsal horn of the spinal cord relative to the
contralateral side following spared nerve injury. By expressing a SUMOylation deficient mutant
of CRMP2 the paw withdrawal threshold to mechanical force was increased for 2 days (Moutal,
Dustrude, et al., 2017). CRMP4 is also SUMOylated. When SUMOylated it shows a reduced
affinity for the Cav1.2 channel. The TRPV1 channel is also SUMOylated during pain. When
SUMOylated at K822 mice were able to develop thermal hyperalgesia. When the SUMOylation
deficient K822R TRPV1 was expressed in TRPV1 knockout mice, the animals failed to develop
thermal hyperalgesia but upon expression of wildtype TRPV1, the development of thermal
hyperalgesia was rescued. This suggests that SUMOylation of the channel is required for
development of inflammatory hyperalgesia (Y. Wang et al., 2018b). Following the spared nerve
injury model of neuropathic pain, the deubiquitinase USP5 shows a reduction in SUMOylation
by SUMO2/3 in the DRG which is associated with a decrease in association with the Cav3.2
channel (Garcia-Caballero et al., 2019). The Kir7.1 channel shows an increase in SUMO1
decoration and a reduction in membrane expression in the spinal dorsal horn following
neuropathic pain. This was associated with an increase in mechanical hypersensitivity,
suggesting that SUMOylation of Kir7.1 contributes to the development of mechanical
hyperalgesia by reducing Kir7.1 surface expression (Lv et al., 2022). An exception to the
increase in hyperexcitability would be CRMP4. CRMP4 is SUMOylated. When SUMOylated it
shows a reduced affinity for the Cav1.2 channel. Association of CRMP4 with Cav1.2 is
associated with an increase in the calcium current and increased thermal pain sensitivity in rats.
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Therefore, an increase in SUMOylation would be associated with a decrease in pain sensitivity,
however the authors did not investigate if SUMOylation of CRMP4 was altered following pain
(Lai et al., 2021).
5.3

Limitations of animal models and heterologous expression systems
In this work both a rodent model and HEK cells were used to examine HCN2

SUMOylation. While using model systems, such as the CFA model of inflammation, can be
advantageous to study ion channels in a biologically relevant system, it can also provide
numerous challenges that can limit the scope of the work. For example, the CFA model of
inflammation is often described as a model of arthritis, as used by other researchers who
previously examined the role of HCN2 in inflammatory pain. However, these authors used a
model where both the hindpaw and the knee joint was injected with CFA. This causes extreme
swelling of the hindlimb. These experiments are hard to gather approval by IACUC as it causes
significant distress to the animal without much increase in answerable research questions than
using the CFA model we used where only the hindpaw was injected. By only injecting the
hindpaw this is really not a model of arthritis, as the inflammation is not in the knees and
hindlimb as experienced in osteoarthritis in humans. However, we did observe results that were
comparable in effect on HCN2 channel expression with a single injection as the previous studies
observed with two. Additionally, by using the animal model we experienced limitations due to
the heterogeneity of DRG neurons. We used crude grouping measures, by using the diameter of
the DRG neurons, to classify neurons as putative c-, Aδ- or Aβ- nociceptors. Using breeding
strategies to directly label neurons by class type would improve this work and allow
identification of the population of neurons that mediate inflammatory nociception and rely upon
expression of HCN2. Additionally, measures such as AAV mediated expression of mutant HCN2

Regulation of HCN2 by SUMOylation

111

channels to study the SUMOylation site involved have significant limitations such as performing
partial laminectomies in order to directly inject AAVs into the lumbar DRGs. This would cause
inflammation from the surgery, as well as the difficulty of removing part of the vertebrae without
causing damage to the spinal cord and ganglia beneath. As such, using heterologous expression
systems to study site specific SUMOylation of HCN2 and the molecular mechanisms
underpinning the changes in surface expression by SUMOylation of HCN2 made the task of
examining SUMOylation much easier as HEK cells do not endogenously express HCN2 or
Kv4.2. However, this is limited by not knowing if K669 is indeed the site that is SUMOylated
following inflammation. Additionally, using stable lines expressing the protein of interest also
can have downsides. For example, the data collected from stably expressing GFP-HCN2 can not
be directly compared to stably expressing GFP-HCN2-K669R due to the copy number of the
plasmid that becomes stably integrated in the HEK cell genome. This could be mitigated by
transiently transfecting HEK cells with the ion channel rather than using stable cell lines.
Additionally in this work to manipulate SUMOylation, we transiently transfected SUMO and
UBC9 plasmids. Because SUMOylation impacts numerous proteins, and a large number of
proteins in the nucleus, the effect of globally increasing SUMOylation this way over several days
can yield results that are non-specific rather than just increasing SUMOylation of the HCN2
channel. An example of this is that we observe a non-significant, but comparable increase in
HCN2 mRNA and the significant increase in HCN2 protein following transient transfection with
SUMO and UBC9. While using K669R mutants did not prevent this increase in protein
expression, it suggests that this effect is due to a non-specific effect of SUMO and UBC9 on
transcription of the channel that is not responsible for the increase in maximal conductance. One
way to get around this was by using SUMO peptide in the patch pipette. This increased SUMO
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for long enough to record a current and lessen the non-specific effects of globally increasing
SUMO over time. Additionally, it allowed us to observe time effects, as we could increase
SUMOylation after the addition of another drug, Pitstop2, to be able to observe if Pitstop2
blocked or occluded the effects of SUMOylation.
In conclusion this work shows that the HCN2 ion channel is differentially SUMOylated
in the dorsal root ganglia following inflammatory pain. How HCN2 channels are regulated by
SUMOylation was then further examined. Here this work shows that SUMOylation of HCN2
alters HCN2 maximal conductance through increased recycling to the plasma membrane by
rab11a mediated slow recycling. Additionally, SUMOylation may have a newly identified role in
regulating ion channels, where c-terminal SUMOylation is acting as a sorting signal to route
channels through the endocytic pathway. Together, this work suggests that SUMOylation may
have impacts on regulating hyperexcitability of ion channels by aiding in regulation of surface
expression and channel density in membranes of excitable cells.
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